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 This work demonstrates peptide-based aggregation mediation of fibril forming peptides, 
notably β-amyloid (1-40), Aβ1-40.  To achieve the goals of this work, Aβ1-40 aggregation was 
governed by ionic strength, temperature, and pH.  After controlling and reproducing Aβ1-40 
aggregate formation (fibrils), each peptide-based aggregation mediator was evaluated for its 
ability to self-aggregate and to possess surface-active properties.  The incorporation of these 
mediators in Aβ1-40 solutions changed the surface tension and produced aggregate complexes of 
mediator and Aβ1-40.  Evidence that Aβ1-40 fibril formation may be mediated by disorder-to-order 
transitions has been observed by layer formation on top of a β-sheet monolayer of another fibril 
forming, but cyclic, peptide.  
 Governance of Aβ1-40 aggregation was performed by controlling the environment of both 
the stock and sample conditions.  Sample containment was important in controlling aggregation, 
as a certain brand of vessels induced Aβ1-40 aggregation.  The introduction of ionic strength and 
temperature also enabled studies at different aggregation stages of Aβ1-40.   
 Each peptide-based aggregation mediator was characterized to determine any self-
aggregation. It was found that AMY-1, developed at Louisiana State University, and an inhibitor 
developed by Dr. Regina Murphy at the University of Wisconsin sparsely aggregated.  AMY-2, 
also developed at L.S.U., favored deposition on mica.  The surface activity of each mediator was 
assessed by tensiometry.  The Murphy inhibitor produced no change in surface activity over a 
wide concentration range, while AMY-1 and AMY-2 displayed surface activity and critical 
micelle concentrations just below 1 mM.  
 The introduction of some mediators caused changes in surface tension to solutions of 
Aβ1-40; Murphy’s inhibitor increased the surface tension, whereas AMY-1 and AMY-2 decreased 
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the surface tension of Aβ1-40 solutions.  Complex formation between each mediator and Aβ1-40 
inhibited fibril development and instead created amorphous aggregates, as evidenced by 
scanning force and transmission electron microscopy. 
 The adsorption of a monolayer of Aβ1-40 onto a β-sheet monolayer of cyclic peptides was 
observed.  These cyclic peptides, initially thought to be fibril inhibitors, were found to be potent 
fibril formers themselves.  These cyclic peptides attached only to exposed sites of highly 
oriented pyrolytic graphite.  The ability for a surface to induce fibril formation may allow a more 









Goals, Research Synopsis, and Background 
1.1 Research Goals 
The primary goal of this research was to develop a methodology that would allow a 
reliable measurement of β–amyloid (Aβ) aggregation behavior in the presence and absence of 
peptide–based aggregation mediators in a near–physiological environment.  It was proposed that 
these mediators can provide alternate non–toxic aggregation pathways.  In order to achieve 
reproducible measurements of β-amyloid aggregation, the initial preparation in these studies 
required samples free of unwanted impurities that could lead to premature aggregation of Aβ. 
After precautionary methods were set in place, each peptide–based aggregation mediator was 
characterized according to the mediator’s surface activity and propensity to self-aggregate. The 
determination of surface-active properties employed the use of tensiometry for determinations of 
surface pressure at varying concentrations. Also, scanning force microscopy was used to observe 
any self-aggregating propensity of the mediators.  
 Upon completion of their characterization, each peptide–based aggregation mediator was 
analyzed for their specificity toward β–amyloid.  Transmission electron microscopy and 
scanning force microscopy was used to define any disruption of Aβ fibril formation.  The 
methodologies described herein provide a foundation for future efficacy studies of newly 
synthesized peptide–based aggregation mediators.  
1.2       Research Synopsis 
1.2.1    Preparation of Reproducible β–Amyloid Stock Solutions 
 The first research aim was to prepare a reliable and reproducible β–amyloid stock 
solution.  The lyophilized peptide was obtained from Biosource (lot number Q9279). A stock 
solution free of impurities such as dust, bacteria, metal content, and premature Aβ aggregates 
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was needed for preparing samples with the same rate of aggregation.  Possible contamination by 
bacteria was addressed by autoclaving all pipet tips and microcentrifuge tubes.  Impurities such 
as metals were minimized by using only salts with purity above 99.99%.  The removal of dust 
from buffered solutions and removal of premature Aβ aggregates was accomplished by filtering 
with non-rinsed inorganic Anotop 0.02 µm filters.  Proper sample containment was also found to 
be important for eliminating premature Aβ aggregation, as it was found that the inner wall 
roughness of microcentrifuge tubes promoted aggregation of Aβ solutions.  After removing any 
conditions that would promote uncontrolled or premature aggregation, the aggregation state of 
the Aβ solutions could then be studied over time and as a function of solution conditions.  
1.2.2    Controlled Aβ Aggregation 
 Aβ aggregate formation could be induced by the presence of high ionic strength 
phosphate buffer at pH 7.4 and elevated temperature.  The buffer used was near physiological 
conditions and consisted of 50 mM phosphate buffer and 150 mM NaCl at a pH of 7.4.  Fibril 
formation of Aβ10-35 or Aβ1-40 under these aqueous solution conditions occurred slowly (3-5 days 
before fibrils observed).  Due to such slow fibril formation, Aβ solutions were placed in an 
Eppendorf Thermostat plus incubator at 50 ºC for up to 24 hours; SFM observed ~300 nm long 
protofibrils after just a 2 hour incubation at 50 ºC.   
1.2.3   Characterization of Peptide–Based Aggregation Mediators 
 These mediators were first characterized for self aggregation.  Utilizing scanning force 
microscopy, it was found that some of the mediators self aggregated.  Surface pressure 
measurements by tensiometry were also made of each inhibitor to determine any surface activity.  
Two inhibitors developed at Louisiana State University had a critical micelle concentration just 
below 1 mM in concentration.  Therefore, all of the mediator/ Aβ studies were conducted at 
concentrations well below mediator micelle formation.   
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1.2.4    Determination of Mediator Efficacy on β–Amyloid Aggregation 
 Once the mediators were characterized individually, they were introduced into solutions 
containing β–amyloid.  The introduction of each mediator into β–amyloid environments was to 
determine their specificity for interacting with β-amyloid and their effect on β–amyloid 
aggregate formation.  The efficacy of each mediator was measured by its ability to form 
amorphous aggregate forms, dissolve fibrils, and inhibit fibril formation.  Out of several 
aggregation mediators, one was found to be highly specific to β–amyloid.  This mediator, AMY-
2, aggregated rapidly with β–amyloid to produce a non–fibrillar amorphous aggregate.  This 
research establishes groundwork for future mediator efficacy studies.  
1.3      Background 
1.3.1    Overview of β–Amyloid 
 Protein misfolding and fibril formation has been noted in several diseases.1  Misfolded 
intermediates of a protein, β-amyloid, have been found to form fibrils in the brain tissue of 
individuals with Alzheimer disease.2  The origin of this β-amyloid protein arises from an 
abundance of enzymatic cleavages of the neuron trans-membrane protein amyloid precursor 
protein (APP).3  The associations of these β-amyloid proteins during the construction of fibrils 
are known to harbor toxic effects upon neuronal cells.4-6   
Proposed options for alleviating the symptoms or progression of the disease involve 
controlling the body’s immune response to Aβ, lowering inflammation of brain tissue, and 
reconstructing already damaged regions of the AD brain.6,7  Many proposals have implicated Aβ 
as the major protagonist of Alzheimer’s disease progression; thus, multiple proposals have been 
made for the elimination or control of Aβ aggregate formation.6,8 The work presented in this 
document is devoted to the amelioration of toxicity through the mediation of β–amyloid 
aggregation.   
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1.3.2    Defining Proteins and Peptides 
 Proteins are central to all living systems due to their involvement in all aspects of cell 
life, immune protection, cell-cell communication, physical support (hair and skin), and muscle 
movement.8,9  Synthetically prepared proteins, shortened or cleaved proteins and proteins with 
unnatural amino acids can be referred to as peptides.  Proteins and thus peptides are built from 
smaller individual amino acid units with each amino acid containing an α-carbon bonded to an α-
amino group, an α-carboxyl group, one hydrogen, and a side chain, R, of varying lengths and 
functionalities.9  The growth of a protein occurs by a condensation reaction between the free 
amine and carboxylic group of the different amino acids to form amide bonds. 9  
1.3.3   The Driving Force Behind Protein Aggregation: Hydrophobic  
           Clustering 
 
 Hydrophobic clustering or collapse is not caused by the mere chance encounters of 
hydrophobic domains, but is driven by the ordering of solvent (water) upon these domains.9  
Water as a solid (ice) is more ordered than liquid water and thus has lower entropy.  When ice is 
melted, liquid water molecules become less ordered and increase the entropy of the system.  
When a hydrophobic domain on a protein or peptide is placed in water, the water molecules are 
disturbed in its immediate vicinity.  These water molecules compete with the hydrogen bonding 
nature of the hydrophobic interactions of the protein and orientate and thus order.  In the 
presence of another hydrophobic domain, these ordered water molecules will become disturbed 
and are released with increased entropy.  Thus, the dispersion of low entropy and ordered water 
molecules into less ordered and higher entropy water molecules provides a thermodynamically 




1.3.4    Protein Folding 
 Protein folding is driven by the need for a protein to sequester its hydrophobic side chains 
from water.9 This sequestering allows the polar groups of the protein’s backbone (NH and 
COOH) to hydrogen bond.    The fold of a protein depends on the types of amino acids present 
within its protein sequence.9  The secondary structure of the α-helix is formed by the hydrogen 
bonding between the NH and CO groups of the same strand whereas the β-strand forms 






          A     B 
Figure 1.1 Secondary Structures of Proteins. (A) α-helix. (B) β-sheet.  The peptide 
backbones (blue line) can intramolecular hydrogen bond (red dotted line) as seen in the α-
helix or intermolecular hydrogen bond (red dotted line) as seen in the β-sheet. 
 
 These β-strands stabilize each other through intermolecular hydrogen bonding forming β-
sheets.10 Tertiary structures build on these secondary structures to form other higher-order 
structures such as β-sheets, βαβ units, β-hairpins, and α-helix bundles.9  The fibrils of β-amyloid 
are composed of mainly β-sheets.11 
1.3.5    Protein Misfolding  
 If a protein were not to fold into some type of conformation, it would not function.9 Thus, 
folding is important to sustain life. However, conformational disordering results from the 
misfolding of the secondary structure of the protein, as in the cases of: Alzheimer’s (β–amyloid 
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protein deposits); amyotrophic lateral sclerosis or Lou Gehrig’s disease (mutations in superoxide 
dismutase protein)12; type 2 diabetes mellitus (Amylin 1-39)13,14; Creutzfeldt–Jakob disorder 
(prion protein)12; Huntington’s disease (Huntington protein)12; Parkinson’s (α–synuclein 
protein); and, familial amyloid polyneuropathy and hemodialysis–related amyloidosis 
(transthyretin protein).15,16  
 Protein misfolding is usually a transition from the normal secondary structure of the 
protein into a β-sheet conformation.16,17  This transition may occur through genetic factors and 
sporadic expressions where conditions such as pH, ionic strength, nucleators, etc. play a role in 
the misfolding of the protein.16,17 Also, as in the case of prion disorders, infectious non-native β-
sheet conformation proteins can induce protein misfolding of other proteins.16,17  The proposed 
lowering of activation energy necessary for protein/surface ordering and facilitation of an 
equilibrium shift toward the β-sheet conformation may help to explain the observed random coil 
to β-sheet transition of Aβ when interacting with lipids and phospholipids.18 Also, metabolites 
such as ozonized cholesterol have also been observed to initiate amyloid protein misfolding.19 
1.3.6    The Misfolding of a Protein May Lead to Fibril Formation 
 Misfolded proteins, especially in β-sheet Conformations can be further stabilized through 
aggregation or oligomerization (fibril formation).16  Protein misfolding has been the primary 
cause of fibril formation in several diseases.1  Fibril formation can be displayed by many proteins 
without much sequence similarity.1  Amyloid fibrils are likely to be composed of β–sheet 
subunits; however, evidence that even an α-helical protein can form fibrils under basic and high 
temperature conditions has been displayed by the protein muscle myoglobin.20   
1.3.7    Mechanism of Aβ Fibril Formation 
 Fibril formation is thought to consist of an aggregation pathway whose genesis contains a 
high entropic barrier and a thermodynamically unfavorable event.21  The aggregation and fibril 
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formation of Aβ consists of a conformational change from random coil (no structure) or α-helix 
into a β-strand.2  The pathogenesis pathway of the prion protein also contains this α-helix to β-
strand transition.22 This transition has been noted to be slow in β-amyloid due to conformational 
minima at both the α and β conformers.16,23  Promotion of this conformation transition may be 
induced by the presence of  non-amyloid artifacts.23   
 The conformational change of β-amyloid is in part due to the hydrophobic collapse of the 
very hydrophobic C-terminal region of Aβ thereby limiting the rate of nucleation, and this 
hydrophobic interaction is further maximized by β-sheet conformation.2,21,24 The formation of 
these nuclei and fibril development are nucleation dependent and the kinetics of such fibril 
formation are determined by nucleation and fibril elongation rate.25 
 The formation of  nuclei as seen in Figure 1.2 is thermodynamically unfavorable, while 
the addition of monomers to existing nuclei is favorable.26  Monomers attach perpendicular to 
the proto-fibril axis with hydrogen bonding occurring parallel to this axis.27  These protofibrils 
contain roughly 1.2 to 2.1 monomers of Aβ 1-40 per each nm length of the protofibril.28  Lateral 
associations of proto-fibrils allow the construction of the mature fibril where the polar N terminal 















1.3.8    Clinical Observations Associated with Alzheimer’s Disease 
 The appearance of lesions or plaque formation in the brain has been identified in the post 
mortem brains of people identified as having Alzheimer’s disease.3  Intracellular deposits are 
commonly found in neurological diseases and are comprised of  τ-protein tangles, but in 
Alzheimer’s disease, neural and non-neural cells contain oligomers of the peptide β-
amyloid.3,29,30  The presence of intracellular β-amyloid is thought to predate the aggregation and 
fibril formation of this peptide outside of the cell.29,30 Extracellular deposits mainly found in the 
temporal lobe of the brain are mostly composed of β–amyloid fibrils, a misfolded and aggregated 
protein structure unique to Alzheimer’s disease.12  These amyloid fibrils have been found in the 
cerebral cortex among the leptomeningeal, meningeal, vascular, and cortical vessels.16,31,32  
Furthermore, β–amyloid presence has been implicated as the main contributor to symptoms 
involving memory and cognition decline.3   
 Early observations of fibrils were found through the Bielschowsky’s silver method of 
staining of post mortem brains in individuals with dementia by Alois Alzheimer.33  Further 
purification and characterization of amyloid fibrils employed congo red staining and polarization 
microscopy.31  One postmortem study of an individual afflicted with Alzheimer’s disease noted 
20 grams of β–amyloid in a 500 gram brain or 10 nmol of β–amyloid per gram of wet tissue.34 
Soluble Aβ has been found to be produced by various cell types, and has been found to circulate 
in the cerebrospinal fluid,35 urine,32 and blood36 of both AD and non–AD individuals.16  
Concentrations of Aβ in AD patient serum are around 30 to 150 nM, 6 times higher than 
individuals without dementia.37   
1.3.9    Genetics 
 Several genetic markers have been found to be associated with AD.  The genes which 
encode for amyloid precursor protein, presenlin-1, presenlin-2, and apoliprotein E have been 
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found to be associated with Alzheimer’s disease.38  Some of these markers provide additional 
clues as to the age at which the onset of AD may occur. A genetic marker located on 
chromosome 21, when presented in a triplicate manner (Trisomy 21), causes both Down 
syndrome and early onset AD.  The onset of AD above the age of 60 has been associated with a 
second genetic marker on chromosome 19.  The onset of AD between the ages of 20 and 50 is 
most likely due to a presenlin 1 mutation on chromosome 14.  Also, the development of AD in 
people above 50 years of age is sometimes caused by presenlin-2 mutation on chromosome 1.   
1.3.10 The Origin of β-Amyloid in Alzheimer ’s Disease 
 The peptide, β-amyloid, originates from a proteolytic cleavage of the amyloid precursor 
protein (APP), a human transmembrane protein reportedly needed for memory.  The cleavage of 
this precursor protein occurs during normal cellular metabolism (Figure 1.3).36  In the healthy 
brain, a soluble fragment of the precursor protein is evolved during a two step cleavage initiated 
a cleavage of APP outside the cell by α-secretase followed by a second cleavage on APP at the 
cell membrane surface by γ-secretase.39 Furthermore, this cleavage occurs between the lysine 
(16) and leucine (17) amino acids located in the hydrophobic KLVFF region, removing the 
viability for Aβ aggregation and producing the peptide fragment p3 (Aβ17-40 or Aβ17-42).40  
  In the pathogenic proteolytic processing of APP in the Alzheimer’s diseased brain, the 
initial cleavage of APP occurs by β-secretase and not α-secretase, leaving a longer cleaved APP 
at the cell membrane surface.39  This longer and cleaved APP region is removed from the cell 
surface by   γ-secretase.39  
 Cholesterol is thought to play a role in this pathogenic route.  During uptake of 
cholesterol by the cell membrane, the membrane swells and allows a more predominant β-
secretase cleavage to take place rather than an α-secretase cleavage of APP.32  90% of the β-
amyloid peptides produced during this later cleavage is (1-40) and 10% is β-amyloid (1-42).3  
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1.3.11  A Description of Aβ Properties 
 The β-amyloid peptide is an amphipathic molecule containing both a hydrophilic N-
terminus and a hydrophobic C-terminus.35 The propensity for β-amyloid to adopt a β-strand is in 
part due to the β–turn (figure 1.2 shown in green) stabilized by a salt bridge between residues 
aspartic acid (23) and lysine (28) and a hydrophobic region (Figure 1.4 shown in red) at residues 
(lysine(16), leucine(17), valine(18), phenylalanine(19), phenylalanine(20)).  Replacement of 
these hydrophobic amino acids with hydrophilic amino acids has been found to inhibit β-amyloid 
fibril development.17  Although these sequences (KLVFF and VGSN) have been found to enable 
β-sheet folding and aggregate β-amyloid proteins, an Aβ protein with both of these same primary 
sequences can also adopt a conformation which is random coil and more vulnerable to protease 
degradation.17  The effect of environmental factors on protein conformation has been identified 
with β-amyloid and several other proteins; work in this area has led to the notion that any protein 
solution above some critical concentration will eventually aggregate as the correct fold of the 
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Figure 1.3 Cleavage of the Amyloid Precursor Protein (APP).  (A) Normal processing  
of APP. (B) Abnormal processing of APP.  
Alpha Secretase Gamma Secretase Soluble MonomerAPP




Figure 1.4 Aβ1-43. The Hydrophobic Region is in Red and the β-turn Region is in Green. 
 
  The β-amyloid structure can not be determined by solution NMR or X-ray 
crystallography due to its insoluble and non-crystalline nature.27  However, X-ray diffraction and 
Fourier-transform infrared spectroscopy (FTIR) both confirmed that short β-amyloid fragments 
favor an antiparallel β-sheet.41  Also, solid state NMR has been able to elucidate the structure of 
β-amyloid which was impossible with solution NMR.27  The solid state NMR method known as 
magic angle spinning further narrows resonances and can determine the structural constraints of 
β-amyloid peptides.27  Solid state nuclear magnetic resonance (NMR) identified full length Aβ as 
containing a cross-β motif which incorporates  in-registry parallel β-sheets.24,41 The amyloid 
protofibril is composed of two interacting cross β-motifs forming a structure with 4 layers of in-
registry parallel β-sheets (Figure 1.5).24,41  
 Local acidic environments (endosomes and lysosomes) in the brain are thought to 
promote fibril formation.42  The propensity for Aβ to aggregate in such low pH conditions has 
also has been noted in vitro where pH environments below the isoelectric point of Aβ (1-43), pI 
5.2, induce fibril forming behavior.43 
 Another condition which induces Aβ aggregation is environmental metal content.44,45  
Both Cu(II) and  Zn(II) coordinate favorably to the histidines located on Aβ monomers and aid in 











            
 




Figure 1.5 A Cross β-motif. Two parallel β-sheets intermolecular interact by side chain-side 
chain interactions.  Salt bridges of each monomer are indicated in blue.  Reprinted with 
permission from Tycko, R. Insights into the Amyloid Folding Problem from Solid-State 




1.3.12 Protagonists of Aβ Aggregation 
Local acidic environments (endosomes and lysosomes) in the brain are thought to 
promote fibril formation.42  The propensity for Aβ to aggregate in such low pH conditions has 
also has been noted in vitro where pH environments below the isoelectric point of Aβ (1-43), pI 
5.2, induce fibril forming behavior.43  
Another condition which induces Aβ aggregation is environmental metal content.44,45 
Both Cu(II) and  Zn(II) coordinate favorably to the histidines located on Aβ monomers and aid in 
Aβ intermolecular interactions.44,45  
1.3.13 Toxicity of Aβ  
 The mature amyloid fibril was previously thought to be the only toxic species of Aβ. The 
body’s immune response to remove Aβ deposits by microglial activation and production of 
arachnidonic acids and eicosanoids from these activated cells induce brain tissue 
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inflammation.37,46  This view is now challenged.  Precursors are now thought to possess more 
toxicity due to their membrane pore forming capabilities.35,47,48 
 Proteins such as prion and the islet amyloid polypeptide (amylin) have been identified as 
cell membrane pore formers.14,49,50  Evidence of this pore forming capability has been followed 
in vitro with lipid bilayer studies; the sonication of Aβ with phospholipids destroys membrane 
fluidity.48  Electrostatic interactions between the cell membrane and Aβ are thought to drive pore 
formation.51  The electrostatic contribution of Aβ  from the protein’s polar N-terminus mostly 
contains positive amino acids (arginine (5), lysine (16), and lysine (28)) that can bind to 
negatively charged and unnaturally exposed inner phospholipids.51  
 Pore formation has been identified as the main contributor of calcium homeostasis 
disruption50, synapse disruption, and uncontrollable nitric oxide release.52  Also, the vasoactive 
nature of Aβ has been noted to affect both the cerebral and peripheral vasculature, resulting in 
reduced blood flow, ischaemia and hypoperfusion.37 
1.4      Overview of Therapy for Alzheimer’s Disease 
1.4.1    Detection of Alzheimer’s Disease Progression 
 The prognosis of AD and defining progression has been hindered in part to the 
unavailability of Aβ in vivo assays.  However, single photon computerized tomography 
(SPECT), has been proposed as a tool for quantifying Aβ aggregate in the brain.53,54  This tool 
would use radioiodinated ligands or γ-emitting technetium complexes as biomarkers for in vivo 
Aβ  detection.53,54   
1.4.2    Removal of Immune Response and Symptomatic AD 
 The body’s immune response to the presence of Aβ is to activate microglial cells.6  These 
cells uptake Aβ and deposit themselves in extracellular compartments of the brain.32  Microglial 
presence has been recorded in plaque formations that are thought to promote fibril formation.32  
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Although cell death may be induced by pore formation involving small Aβ aggregates, 
microglial activation indirectly causes even more harm to the brain by providing more nucleators 
for fibril development and cause brain inflammation.  The use of anti-inflammatory drugs to 
limit brain inflammation has been effective, but heavy or long term application of such therapy 
may harm kidneys and other organs.6 
1.4.3   Controlling Aβ Production  
 It is proposed that the production of Aβ can be slowed by decreasing the amount of APP 
expressed or eliminating its proteolytic cleavage.  Removing APP expression entirely would 
unfavorably affect other needed proteins such as the Notch protein.55  However, a lithium 
secretase inhibitor has been found to reduce APP processing and production, but not interfere 
with the Notch protein.55  Another avenue is focused on blocking the cleavage of APP.56  The 
inhibition of cleavage of APP by β- and γ-secretases has been achieved with lipophilic 
dimethylaminoethyl tetralin and cyclohexylalanine–based statine.  Another γ–secretase inhibitor, 
fenchylamine sulfonamide, was observed to eliminate β–amyloid production in cell culture.57  
1.4.4    Aβ  Vaccination 
 Auto-antibodies for β-amyloid proteins have been found in persons with AD.  Antibodies 
or immunoglobulins are a part of the humoral immune response and are produced by plasma 
cells in a response to the appearance of a foreign motif (antigen or immunogen).9  However, the 
amount of antibodies may not be enough to have a huge impact.  Auto–antibodies for the 
peptides Aβ 25-35 and Aβ 1-42 have been found in serum of persons with Alzheimer’s disease.58  
The mucosal or nasal administration of transgenic mice containing platelet–derived growth 
factor promoter APP, PDAP with Aβ protein reduced the Aβ plaque of these mice later in life.59   
Active vaccination of humans for Aβ was first employed by Elan pharmaceuticals.60  The 
injections of Aβ1-42 produced both antibody and T-cell responses by the patient; however, the 
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trial was ended due to hemorrhaging and brain inflammation.60  Therefore, active vaccination 
may be replaced by a more passive one.  A passive approach to Aβ vaccination was also 
developed by Elan pharmaceuticals where Aβ antibodies were injected into mice.60  However, a 
possible side effect would be the development of an antibody for the Aβ antibody itself.60 
1.4.5    Initiation of Aβ Aggregation 
 Plaque formation in AD cannot be formed by Aβ alone and is stabilized by non-amyloid 
components.  Such non–Aβ components are: polysaccharides, proteins (serum amyloid protein), 
and heavy metals such as Cu and Zn.16,61 Polysaccharides such as glycoaminoglycans are thought 
to bind plaques together by chaperoning and depositing with Aβ.61   Mice that were given a drug 
to disrupt this interaction, NC–75 or Alzhemed, had lower plaque burden.61  Proteins such as 
serum amyloid protein are known to coat and maintain the integrity of the senile plaque; 
removing serum amyloid protein would allow normal uptake of the now exposed senile plaque.61  
 Metals have multiple relationships with Aβ by providing nucleation sites, and enhancing 
both Aβ aggregation and the stability of Aβ deposits.44  Thus, an agent that can remove 
unnecessary metals would potentially destabilize plaque formations.  Since Cu (II) and Zn (II) 
have been found to bind favorably to the histidines located in β-amyloid, treatment with metal 
chelating agents may help to destroy the integrity of amyloid plaque formations.44,45  
1.4.6    Dissolving Pre-formed Amyloid Fibrils 
 Fibril dissolution has been proposed as a viable option for eliminating plaques.62,63  
However, the subunits of these fibrils have been identified as being more toxic than the mature 
fibril and may increase the amount of these more toxic subunits.29  These subunits, oligomeric 
Aβ, have been found to be the main contributor of membrane pore formation and cell apoptosis. 
Studies with α–synuclein suggest that increasing the rate of the fibril forming pathway in order to 
prevent smaller oligomeric aggregates from forming pores in human cells may be an effective 
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strategy.64 Thus, successful fibril dissolution by constructs such as poly–L–lysine, polyethylene 
glycol, and peptides containing proline residues65 also need to keep smaller subunits from 
causing cell membrane damage.62  
1.4.7    Aβ Aggregate Mediation 
 Elimination of the fibril forming pathway of Aβ has been proposed using small 
molecules66, peptide–based constructs, and surfactants.  The mediator should have the ability to 
regulate β-amyloid aggregation and provide an alternate aggregation pathway which would result 
in a non–toxic form of aggregate (Figure 1.6).   
1.4.8    Small Molecule Aβ Aggregate Mediation 
 Small molecules such as the dye congo red, the antibiotic rifampicin67 and anthracycline, 
4’–iodo 4’–deoxydoxorubicin, have been found to prevent Aβ aggregation.61,68  Congo red has 
been observed to decrease the thermal folding temperature of the Aβ protein and inhibit fibril 










Figure 1.6 Mediation of the Aβ Aggregation Pathway. Blue arrow indicates pathway to  
fibril formation. Orange arrow indicates the formation of amorphous/non-fibril aggregates 
of β-amyloid by aggregation mediators. 
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1.4.9    Mediation of Aβ Aggregates by Surfactants  
 In the presence of sodium dodecyl sulfate SDS micelles, Aβ1-40 has been found to remain 
monomeric and in an α-helix state while resting upon the periphery of the SDS micelle.70,71  This 
conformation disables the pathway for amyloid fibril formation.70,71 Other detergent molecules 
such as hexadecyl-N-methylpiperidinium (HMP) bromide have been shown to inhibit Aβ 
aggregation.34   It was found that HMP bromide was specific to β–amyloid as it did not inhibit 
the formation of fibrils by other amyloidogenic peptides.34  
1.4.10 Peptide-Based Aβ Mediation Aggregation 
 Peptides which mimic β-strands have been prepared with the idea of forming a dimer 
with Aβ monomers by the self-formation of β-sheets and hydrogen bond action with the Aβ.72  
Other peptides have been designed which incorporate amino acids with substituted methyl 
groups or alternating synthetic amino acids with large functionalities to also dimerize and 
prevent subsequent hydrogen bonding of Aβ. 
 A hydrophobic region of β-amyloid, residues 16-20, has been identified as a major 
contributor to amyloid fibril formation.2,8,73-75 This region, KLVFF, has been proposed as a 
useful recognition template for designing peptide-based aggregation mediators.8,40,73,75,76 Murphy 
et al. have constructed a peptide-based aggregation mediator containing the KLVFF region and a 
soluble oligolysine unit.  This mediator allowed the regulation of Aβ aggregation and Aβ toxicity 
through specific binding and fibril inhibition.2,8,75  
 Incorporating amino acids with substituents that disable hydrogen bonding between β-
amyloid molecules has been found to inhibit fibril formation. A peptide-based aggregation 
mediator containing alternating amino acids with N-methyl groups throughout the hydrophobic 
KLVFFAE region, Aβ16-22, inhibited fibril formation.77  Another mediator using N-methylated 
amino acids in the peptide Aβ25-35 has also been found to prevent fibril formation.78    
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 The peptide based aggregation mediators designed and employed in the work presented 
here were obtained from Dr. Robert Hammer et al. at Louisiana State University.  They contain 
alternating Cαα-disubstituted alpha amino acids in the hydrophobic KLVFF β-amyloid region.79,80 
These mediators were designed to hydrogen bond to the β-amyloid monomer on one side and 
disable any subsequent hydrogen bonding of β-amyloid by providing steric hindrance due to 
large functionalities of the synthetic amino acids.79,80 These peptide–based aggregation mediators 
were compared to the mediators developed by Dr. Regina Murphy, University of Wisconsin, 
who also used the KLVFF region as the main target of mediation. 
1.4.11 Viable Peptide-Based Aggregation Mediators 
 The viability of a peptide-based aggregation mediator is determined by its ability to cross 
the blood brain barrier and withstand in vivo conditions which could lead to mediator 
degradation.63 Low molecular weights are needed for crossing the blood brain barrier and the 
transport must be done without any degradation of the aggregation mediator.63  D–enantiomeric 
peptides have been found to be more stable in vivo than L–amino acids due to their ability to 
withstand proteolysis.63,65,73   
1.4.12 Overview of Studies for Detecting β–Amyloid Aggregation and Cell Toxicity 
 
Cell toxicity studies provide information on the ability of introduced drugs to control or 
eliminate the inherent toxicity of Aβ fibril formation.78  Such studies use the dye 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction within the 
mitochondria as a measure of cell viability.78  Cell apoptosis is observed if the normal reduction 
of this dye decreases.78   
1.4.13 Binding Assays 
 Irreproducibility and high sample consumption has hampered past use of binding assays 
for measurements of mediator efficacy.81  The use of surface plasmon resonance (SPR) has 
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overcome these disadvantages.81  In SPR, an immobilized array of β–amyloid of a chosen length 
such as Aβ 10-35 is attached to a carboxymethyl dextran matrix.81  Once an array of Aβ monomers 
are attached to the matrix, introductions of mediators can be made to determine their binding 
affinity to Aβ.8,81  
1.4.14 Size and Growth Determinations of β–Amyloid Aggregates in Solution 
 
 Dynamic light scattering of β-amyloid containing solutions have been used to determine 
the kinetics of fibril growth in solution.25,82-87  Monomeric diffusion coefficients have been 
reported in the range of 6 x 10-7 and 17 x 10-7 cm2s-1 depending on the solvation of the 
monomer.82  Molecular weight determinations of Aβ and Aβ/mediator aggregates can be 
obtained with analytical ultracentrifugation and size exclusion chromatography.25,88   
1.4.15 Determination of Amyloid Aggregate Size Adsorbed on Surfaces: Microscopy 
Studies of β–Amyloid  
 
 Transmission electron microscopy (TEM) and scanning electron microscopy (SEM) have 
been used to determine the structure of Aβ while physically adsorbed to a prepared 
substrate.6,34,65  Both TEM and SEM techniques employ non-amyloid materials (staining, 
coating) in order to image the amyloid aggregates on the surface.6,8,38,89-95 
Another microscopy technique, scanning force microscopy (SFM), has been exposed as a 
useful tool in determining β–amyloid aggregate morphology. Microscopy techniques are now 
focused on imaging amyloid in their native environment such as with  in situ tapping mode 
SFM.18   
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Chapter 2  
Materials and Methods 
2.1       Experimental  
2.1.1 Chemicals and Products 
 The β-amyloid peptides, Aβ10-35 (vendor number 03-153, 2902 g/mol),   Aβ25-35 (vendor 
number Q8160F, 1060 g/mol), and Aβ1-40 (vendor number 03-136, 4331 g/mol, trifluoroacetic 
acid preparation, and lot numbers Q9279, Q10501) were obtained from Biosource 
International.  Amylin fragment (20-29), (vendor number A-6097, 1009.1 g/mol) was 
purchased from Sigma-Aldrich.  The KOH, phosphate buffer, and stock solutions of β–amyloid 
were filtered using an Anotop filter (sterile, 0.02 µm pore size/10 mm diameter) from 
Whatman. Deionized water was prepared by passing distilled water through a reverse-osmosis 
filter and then a series of organic and ion-exchange filters (Nanopure, Barnstead) to yield water 
of 18 MΩ cm resistivity.  The 0.02 µm pore size Anotop filter was attached to a 3 mL latex–
free Becton Dickinson & Co. syringe fitted with a cut pipet tip to deliver the solution. The low 
ionic strength phosphate buffer was prepared by diluting 15 M 99.999% phosphoric acid from 
Aldrich with 18 MΩ cm water, raising the pH of this diluted phosphoric acid solution to 7.4 
with 1 M KOH, and then adding 18 MΩ cm water to achieve the desired concentration of 
phosphate buffer. The high ionic strength buffers were made with Puratronic metals basis salts 
(NaCl, NaF, and NaNO3) from Alfa Aesar with purity greater than 99.99%. The 1 M KOH was 
prepared by dissolving semiconductor grade KOH pellets from Aldrich in 18 MΩ cm water. 
Samples were stored under nitrogen using non-colored Dot Scientific Inc. flat-top/graduated, 
polypropylene, 1.5 mL microcentrifuge tubes (vendor number 509-ftg) or in some instances, 
where noted here, in Sarstedt o-ring capped, 1.5 mL microcentrifuge tubes (vendor number 
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72.692). The pipette tips used were 1–200 µL, RNAse/DNAse-free, non-colored (Corning Inc.) 
pipette tips.   
2.2 Methodologies 
2.2.1 Proper Weighing of Amyloid Peptides 
 When adding the peptide to microcentrifuge tubes for dispensing purposes, it was 
noticed that the peptide is very much like charged dust; it tended to “jump” to things that came 
into contact with it. This attribute, coupled to β-amyloid and amylin peptides being fluffy, 
makes it difficult to handle. We adopted a method for transfer of the solid peptide that avoids 
some of these issues. We have found that gentle tapping of the container, usually a glass vial 
containing the lyophilized peptide, adjoined to an adjacent microcentrifuge tube allows for 
clear and easy transfer of the peptide. This procedure also prevents possible contamination 
associated with traditional weighing methods. 
2.2.2 Preparation of β–Amyloid Stock Solutions  
 After weighing the peptide, it must be dissolved prior to introduction into the phosphate 
buffer. Attempts at dissolving the peptide in either phosphate buffer or phosphate buffer with 
added ionic strength (PBS), was found to cause premature or enhanced aggregate formation, 
supported by the observance of turbid solutions immediately upon dissolution of the β-amyloid 
solid. In an effort to prepare aqueous solutions of varying concentrations of β-amyloid under a 
variety of solution conditions, it became necessary to make fairly concentrated aqueous stock 
solutions of β-amyloid free of organic solvents (such as dimethyl sulfoxide–DMSO). A 
previous report has briefly commented on preparing such solvent–free stock solutions of Aβ1–
40.1  
 To eliminate aggregate formation from occurring during preparation of β-Amyloid, we 
dissolved the peptide in 0.02-micron-filtered Anotop filter obtained from Fischer VWR (vendor 
 30
number 28138-011) 10 mM semiconductor grade KOH “high pH” followed by vortexing with 
a Daigger Vortex Genie 2 until no particulates were observed. Approximately 20 µl of the 
filtered stock is used for amino acid analysis (AAA); 10 nanomoles or more peptide are needed 
for AAA detection.  
2.2.3    Preparation of Low-Aggregation State Amyloid Solutions 
 Low-aggregation state amyloid solutions were prepared by introducing the β-amyloid 
stock solution to filtered phosphate buffer and phosphate buffered saline solutions. The 50 mM 
phosphate buffer and phosphate buffer with added “salt” solutions were filtered through 0.02 
µm Anotop filters (Whatman) before combining with the filtered Aβ stock solution in KOH to 
produce the desired concentration of Aβ peptide. All samples were placed under nitrogen 
immediately after preparation to eliminate exposure to atmospheric carbon dioxide to ensure no 
development of carbonic acid and thus drops in pH within the solution. The samples were 
placed in 1.5 mL microcentrifuge tubes, which were then capped and wrapped with Parafilm. 
The Parafilm–sealed sample containers were then placed in a Nalgene 1000–mL, wide–mouth 
container and the Nalgene container subsequently sealed with Parafilm. The Nalgene container 
was periodically purged with nitrogen so as to prevent changes in peptide sample pH.  
2.2.4 Determination of Amyloid Stock Solution Concentrations 
 
 Amino acid analysis (AAA) was used here to note possible differences in the 
concentration of Aβ in aqueous solutions before and after filtration through the 0.02 µm filters. 
In the amino acid analysis method used here, the peptide-containing sample was hydrolyzed, 
and the amino acid content of the individual residues was compared to known amounts of a 
standard, such as the nor-leucine amino acid. The amount of amino acids in the hydrolysate was 
determined by chromatographic separation (Dionex 6550 with acetonitrile-water gradient 
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containing 0.1% trifluoracetic acid, four replicates performed with the average and standard 
deviation reported here) coupled to a electrochemical detector (Dionex ED50). In order to 
ascertain the possible effects of filtering on Aβ solutions, a sample of Aβ10–35 in  ~10 mM KOH 
(pH 11.7) solution was prepared for amino acid analysis. Half of this sample was filtered with a 
0.02 µm Anotop filter, and the other not. Both the unfiltered and filtered samples were 
hydrolyzed and subsequently analyzed for amino acid content. The peptide concentration for 
the unfiltered Aβ10–35 was found to be 1.76 ± 0.01 mg/mL, whereas that of the filtered Aβ10–35 
was 1.74 ± 0.01 mg/mL, leading to an approximate loss of 20 µg/mL or 1.1 % of peptide, 
which is negligible. 
 AAA analysis was also used for determining whether any attribute of the longer and 
faster aggregating amyloid protein protein Aβ1-40 would result in loss during the filtering 
process. Aβ1-40 was dissolved in 10 mM KOH (pH 11) and filtered using an Anotop 0.02 µm 
filter.   The unfiltered portion was 1.62 ± 0.03 mg/mL whereas the filtered portion was 1.55 ± 
0.03 mg/mL noting a higher but small 70 µg/mL or 4% loss of peptide through filtering.  
2.2.5 Preparation of Protein Aggregate-Inducing Solution Conditions  
 
 The addition of “salt” to the phosphate buffer was achieved using metals–basis or 
99.99+% pure salts to reduce the possibility of complexation of the peptide with labeled 
impurity metal ions such as zinc, copper, or aluminum. Such metal ions have been shown to 
induce aggregation of β–amyloid peptide.2  
2.2.6    Preparation of Amylin Stock Solutions 
 The normal stock solution preparation for β–amyloid has been used for preparing stock 
solutions of another fibril forming peptide, amylin (20-29). The full length of this peptide, 
amylin (1-37), (Sigma vendor number D-2162) was found to rapidly aggregate when basic 
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potassium hydroxide solution was added to lyophilized solid amylin1-37 material. The two 
cysteine amino acids at residues 2 and 7 in amylin1-37, pKa of 8.5, enable the formation of a 
disulfide bridge. However, the amylin20-29 human fragment does not contain these two amino 
acid residues and was found to readily dissolve in the basic KOH. The peptide can easily be 
filtered with a 0.02 µm Anotop filter and this peptide was found to form fibrils over time when 
added to a salt containing buffer.  
2.2.7    Preparation of Peptide-Based Aggregation Mediator Solutions 
 The peptide-based aggregation mediators were dissolved in 18 MΩ water and filtered 
with a 0.02 micron Anotop filter into an autoclaved microcentrifuge tube.  The concentration of 
the mediators was calculated to be 1mM, (verified by AAA). These mediator solutions were 
placed in a refrigerator at 8 ºC.    
2.2.8 Determining the pH of Minute Volumes of Peptide-Containing Solutions 
 The pH of each final sample was determined using a miniature (18 gauge) pH 
combination electrode model number MI–413 (Microelectrodes, Inc.) connected to a Denver 
Instrument Ultra Basic–5 pH meter. This miniprobe allows determinations of pH in microliter 
volume solutions. This is important, as most β-amyloid/aggregation mediator studies involve 
samples of much less than 1 ml of total volume. For pH measurements, a 5 µL aliquot was 
taken out of the sample and placed as a droplet onto a strip of buckled Parafilm; measuring the 
pH of the solution directly on a flat surface increases the possibility of mechanical breakage of 
the thin glass probe. The pH was measured before any analysis and included measurements 
before and after incubation periods.  
2.2.9    Storage of β-Amyloid Samples for Analysis 
 All samples were placed under nitrogen to keep the solution pH from decreasing as a 
result of carbonic acid formation caused by exposure to atmospheric carbon dioxide.  The 
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samples were placed in 0.5–ml microcentrifuge tubes, which were then capped and wrapped 
with Parafilm for storage.  The microcentrifuge tubes were placed in Nalgen containers (vendor 
number MX21666/1000ml) which had two drilled holes with fitted septa. An (18-gauge) needle 
was placed in one of the two septa for exhaust; the other septum had a needle connected to a 
continuous nitrogen purge. 
2.2.10 Preparation of β–Amyloid Samples for Analysis by Scanning Force Microscopy 
 (SFM) 
 
 Samples were adsorbed onto two types of surfaces, atomically flat and hydrophilic mica 
(ASTM V–2 Grade 3 Ruby muscovite, Lawrence & Co.) or hydrophobic highly oriented 
pyrolytic graphite (HOPG) obtained from Arthur Moore at Advanced Ceramics Corporation.  
Cleavage and exposure of interior mica planes (which are atomically flat over large areas and 
ideal for SFM imaging) were achieved by placing a razor blade in the middle of the sheet edge 
layers of a 1 cm2 piece of mica separating the layers by gripping one side with a pair of 
tweezers.  After cleavage, the mica was blown dry with nitrogen to remove any particulates due 
to the cleaving process.  A sample aliquot of 5 µL was then placed on the freshly exposed mica 
and allowed to remain for 5 minutes, unless otherwise noted.  A fresh HOPG surface was 
prepared by placing a section of one-sided Scotch tape on one side of the graphite.  The tape 
was then pressed and removed to reveal a smooth, shiny, and clean surface.  Sample application 
on HOPG was the same as mica. 
 After a 5 minute adsorption step in most cases, the sample/substrate was rinsed with 
400 µL of deionized water (fibrils or aggregates will remain adsorbed as noted later) followed 
by tilting the substrate and placing its edge on a Kimwipe to wick away the water.  After the 
water rinse, the sample was gently blown dry with a stream of nitrogen.  The mica and HOPG 
samples were then placed sample-exposed face up on a 15 mm metal specimen disc from Ted 
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Pella Inc. (vendor number 16218) with double–backed tape (Gluespot by Digital Instruments, 
catalog reference STKYDOT). When ready for imaging, each specimen disc was placed on top 
of the piezoelectric scanner of the SFM instrument.  Samples not immediately imaged were 
stored in semiconductor wafer containers from Entegris (vendor number H22-101-0615 tray 
and number H22-10-0615) under an ordinary lab ambient environment. 
2.2.11 Preparation of Samples for Transmission Electron Microscopy 
 All substrates, storage boxes, lens tissue, and chemicals used for transmission electron 
microscopy were purchased from Electron Microscopy Sciences. For electron microscopy, the 
sample solutions were adsorbed onto a thin carbon coated collodion layer placed on a copper 
grid.3 The collodion coating was used to keep the sample on the grid; deposition of carbon onto 
this grid was done to ensure thermal stability of the film. In order to make the collodion film, a 
pool of water was placed in a 150 mm x 15 mm polystyrene petri dish cover from Fisher 
(vendor number 08-757-14). The water was added until almost spilling over the sides of the 
petri dish. A sheet of Ross optical lens tissue (vendor number 71700) was placed on top of the 
pool of water and gently pulled across the surface to remove any particulates on the surface. A 
thin film of collodion was prepared by dropping roughly 20 µL of non-filtered 2% Collodion in 
amyl acetate (vendor number 12620-00) until the  solution began to solidify and thicken on the 
surface. After the collodion film was formed, several 400 mesh Cu grids (vendor number 
G400–Cu) were placed onto the film and allowed to stand. Removal of the coated grids was 
accomplished by placing the paper used to separate Parafilm layers over the Collodion 
membrane until the entire paper was wet; this was to ensure proper adhesion of the grid to the 
Parafilm paper. The paper was then removed causing the grids and adsorbed Collodion film to 
be removed from the water/Collodion interface. After adsorbing the film onto the grid, the grids 
were placed in Petri dishes for 24 hours under ambient conditions to dry. A bench top Turbo 
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Denton vacuum evaporator was used to coat these grids with carbon in order to keep the 
Collodion from being vaporized by the thermal energy generated during the bombardment of 
incident electrons in the TEM.  
 Samples for TEM analyses were then prepared by placing the carbon/Collodion coated 
grid faced down on a 5–µL sample droplet for 1 minute. After this step, the excess droplet was 
wicked away by placing the edge of the grid onto a sheet of optical lens tissue. The grid is then 
placed on a droplet of 0.02 µm Anotop (Whatman) filtered 2% uranyl acetate (vendor number 
22400) for a few seconds. The grid was then wicked away of excess liquid and placed in a grid 
storage box, (vendor number 71137), which holds 100 (2-3 mm) specimen support grids.   
2.2.12 Preparation of Solutions for Tensiometry 
 Both the Du-Nuoy ring and Wilhelmy plate methods were used in these studies.  For 
Wilhelmy sample preparations, the aliquot was placed into a 6 mm x 50 mm Kimble test tube, 
wrapped with a Kimwipe, and centrifuged in a larger plastic tube.  The tubes containing the 
sample were centrifuged for 10 minutes at 2000 x G.  After centrifugation, a gel loading pipet 
tip from United Scientific Products, Inc. (vendor number TGL-1000) was used to remove the 
supernatant of each sample.  This supernatant was placed on a 25 mm watch glass from Aldrich 
(vendor number Z 50,919-1).  Only 120 µL of sample was needed to make a measurement with 
a 1 cm x 2 cm Wilhelmy paper plate obtained from NIMA technology.  The watch glass was 
immobilized on the back side of a scintillation cap to eliminate the watchglass from moving by 
capillary forces exerted from the Wilhelmy plate.   
 The plate was hooked onto the bottom of a hooked 50 mm long and 65.9 mg in weight 
platinum iridium wire (California Fine Wire Company vendor number 12881).  The eye on top 
of this wire is fastened on the NIMA Technology type PS4 surface pressure sensor.  The 
Wilhelmy plate method was used along with a Lab View program.  After the solution was 
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placed on the 25 mm watch glass, the free plate was zeroed and brought to the surface of the 
droplet. Upon saturation, the plate was then lifted and zeroed.  The plate was then lowered to 
the droplet; the surface tension was measured when the plate was just below the meniscus of 
the solution.  Consecutive measurements were made by removing the plate and bringing the 
plate back to the surface of the droplet; each solution was measured 5 times. 
2.2.13 Preparation of Samples for Dynamic Light Scattering 
 Sample tips, microcentrifuge tubes, and cells were rinsed with 0.2 micron Anotop-
filtered 18 MΩ water to remove dust particulates.  Removal of dust was important to remove 
unwanted scattering events that will eliminate coherence and destroy determinations of the 
diffusion coefficient and therefore size of the sample of interest.   
 When a sample was ready for scattering measurement, the sample cell was inserted into 
a bath of index matching solvent such as toluene; the cell was gently wiped with cotton fabric 
or lens cleaner to clear the windows and prevent scratching.  The toluene must be 0.2 micron 
filtered to remove any dust particles that can scatter laser light.   
2.2.14 Preparation of Samples for Reflection-Absorption Infrared Spectroscopy (RAIRS) 
 
 Reflection-absorption infrared spectroscopy (RAIRS) was conducted on a Thermo 
Nicolet Nexus 670 FTIR at an angle of 86º.  A large and smooth piece of HOPG, prepared by 
removing the uppermost layer of the HOPG with tape, was used for surface analysis of peptide 
adsorption.  Approximately 500 µL of 500 µM of each peptide was spread across a freshly 
cleaved HOPG surface and adsorbed for 5 minutes.  A KBr pellet was made by mixing KBr 





2.3       Instrumentation 
2.3.1  Microscopy in General 
 Optical microscopes have enabled the determination of structures in the micron range.  
However, the visible wavelength of light (380-780 nanometers) used for such studies limits the 
detection of objects in the sub-micrometer range.4  Thus, imaging capability and resolution 
have increased with the employment of electron microscopy.  The magnifications of 
microcopies increase when registering the scattering of the much shorter de Broglie wavelength 
of electrons (picometers) from a surface as in TEM or SEM.4  These techniques, however, 
require the use of delicate sample preparation and a vacuumed environment. 
 The development of the scanning tunneling microscope (STM) which uses platinum/ 
iridium wire to provide a junction between the tip of this wire and a conductive surface can be 
used for determining structures adsorbed to surfaces at nanometer resolution.5 However, this 
technique was limited to work on conductive surfaces.  Thus, this technique led to the 
development of the scanning force microscope (SFM) which collects information on the van 
der Waals interactions between a cantilever and a surface.   
 Microscopes can be divided into two general categories: scanning and simultaneous 
imaging.  Transmission electron microscopy can be conducted by both avenues, and the 
simultaneous imaging offered by TEM was used in the work presented here.  Other microscopy 
techniques that use the scanning method are the scanning electron microscope (SEM) and 
varying modes of the scanning force microscopes, which will be further discussed. 
2.3.2 Transmission Electron Microscopy 
 Research employed a JEOL 100 CX transmission electron microscope at an electron 
acceleration voltage of 80 kV.  All film, developer, fixer, and other solutions were obtained 
from Electron Microscopy Sciences (EMS).  The TEM film used was a 4489 multi-pack Kodak 
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electron microscope film (vendor number 1662238) with dimensions of 3.25" x 4" and an 
emulsion number of 31300201.  D–19 developer by Kodak (vendor number 74200) was used to 
develop the film.  This development was followed by Kodak Rapid Fixer, (vendor number 
74312).  After this step, the film was submerged in Kodak Photo–Flow solution (vendor 
number 74257) and allowed to dry.  The negatives were then scanned into a computer using a 
DUOSCAN T/200 AGFA scanner operated by Fotolook 3.2 V3.60.60 software program on a 
PC.  Adobe Photoshop 7.0 was used to further enhance the brightness and contrast of the 
images.  Magnification bars were placed onto the pictures(1200 d.p.i.) and exported together to 
ensure correct representation of scale. 
2.3.3 Theory of Transmission Electron Microscopy 
In transmission electron microscopy (TEM), an electron gun containing a tungsten 
filament is used to generate electrons.  The electrons are generated by thermionic emission 
when a negative high voltage, direct current is applied to the filament.  A Wehnelt cylinder or 
shield completely surrounds this filament except for a small opening (2 to 3 nm in diameter) 
and operates at a higher negative voltage than the filament.  The opening in the shield is to 
direct the electrons toward the anode just below the shield as seen in Figure 2.1.  Once the 
electrons pass the anode, they are focused by the condenser lens onto the sample grid.  The 
sample grid is usually a copper mesh grid with a support film.  Before TEM analysis, 
specimens of interest are adsorbed to this film and typically stained using a heavy metal salt 
(uranyl acetate or phosphotungstic acid) which have high atomic numbers capable of scattering 













Figure 2.1 TEM Electron Gun Assembly 
 
Figure 2.2 depicts the transmission of electrons through the condenser lens to the 
sample grid.  Any electrons not blocked by the sample upon the grid are then focused again by 
the objective lens.  The objective lens and aperture define the aperture angle and depth of field. 
Once the image is formed, the electrons are passed through the intermediate (diffraction) lens 
to aid magnification.  A final passage through projector lens further magnifies the electrons and 
increases the depth of focus.   
 After the electrons have passed the projector lens they are deposited onto a fluorescent 
screen containing a cellulose nitrate or gum arabic matrix containing fine ZnS/CdS particles.  
The small λ electron particles bombard this screen and cause an emission of longer λ which can 
be detected by the human eye.  The resolution of this image (35-50 µm resolution on the screen 
compared to the 200 µm by the human eye) depends on the grain size of the embedded particles 









which can open and close to expose the photographic film.  Advancement of the film opens the 
shutter allowing electrons to penetrate the film’s AgBr gelatin matrix.  These electrons convert 
the AgBr to metallic Ag. Further production of metallic Ag occurs during the development of 
the film to provide the contrast needed for the image.  
 
   
    











Figure 2.2 Image Formation During TEM Experiment 
2.3.4 Scanning Electron Microscopy (SEM) 
 Another microscopic technique which uses electrons for image formation is the 
scanning electron microscope (SEM).6  Unlike TEM, the SEM uses its electromagnetic lenses 
to demagnify and focus electrons onto a conductive surface.6  The conductive surface can be a 









natively.6  The focused area of electrons is scanned in a raster pattern, as seen in Figure 2.3, 
across the surface causing the emission of low-energy secondary electrons from inelastic 
scattering events.6,7  
 







Figure 2.3 Raster Pattern Offered by Scanning Electron Microscopes 
 The collection of these electrons by a secondary electron detector are then converted 
into pixels on a monitor.6  The brightness of each pixel defines the amount of secondary 
electrons detected.6  Due to its depth of field, SEM allows for imaging of specimens of varying 
thickness.6  
2.3.5 Scanning Tunneling Microscopy 
 The formation of an image using the “raster pattern” technique across a surface has also 
been applied to scanning tunneling microscopy (STM).  However, instead of scanning the 
surface with a focused amount of electrons, the surface is probed by a metallic wire (Pt/Ir) at a 












Figure 2.4 Schematic of a Scanning Tunneling Microscope 
The distance between the tip and the surface is obtained by controlling the current 
between the tip and sample junctions through an applied voltage, Figure 2.4.  The current is 
therefore a function of the bias voltage, V, the constant characteristic of conductors, C, and the 
spacing between the apex of the tip and the highest atom on the surface, d as identified in 
Equation 2.1.  This movement of the tip across the surface is obtained by piezoelectric motion 
which is detailed further under the scanning probe microscopy section. 
Equation 2.1 It = Ve-Cd 
2.3.6 Scanning Force Microscopy 
 A Nanoscope III Multimode scanning force microscope was used in Tapping Mode. 
Noncontact high frequency silicon cantilevers (NSC–15, MikroMasch) were used to obtain the 
SFM images. The non–contact NSC15 silicon cantilevers produced by MikroMasch used in 
these studies contained a reflective aluminum backside coating. These tips had a radius of 
curvature of 10 nm, a full tip cone angle less than 20º, and a tip height of 15-20 µm. The typical 
resonant frequency of these NSC15 cantilevers was 325 kHz with a force constant of 40 N/m.  
The scan parameters utilized were: 1.0-1.5 Hz scan rate and 0.6 integral and 0.2 proportional 








  A scan size of up to 125 µm x 125 µm can be obtained with the vendor’s (Digital 
Instruments) software and a J–type piezoelectric scanner. After capturing the SFM images, a 
flatten procedure was performed, and the dimensions of the aggregates were determined using 
the manufacturer’s software. Topographical images are shown in grayscale, with brightest 
points in the image being the tallest features. The heights of aggregates are determined using a 
bump analysis algorithm. 
2.3.7 Theory of Scanning Force Microscopy 
 A ceramic piezo-electric tube is used to produce the raster pattern used in probing the 
surface in scanning probe microscopy.  Applying AC voltages to the conductive X and Y 
portions of the tube, as seen in Figure 2.5, distorts the shape of the piezo-electric tube and thus 








Figure 2.5 Ceramic Scanner Piezo-electric Tube  
 Scanning force microscopy, SFM, also known as atomic force or scanning probe 
microscopy, offers the ability to visualize β–amyloid aggregates on a surface. Such a method 
can be used to follow the aggregation behavior in solution by merely adsorbing the aggregates 
formed in solution onto an appropriate support (substrate). Information regarding the length 
and height (diameter) of aggregates can be obtained from SFM images. Because adsorbed 
 44
peptides and other biological materials are “soft”, a non destructive SFM method is required, 
thus non-contact or Tapping Mode SFM is used. Tapping Mode SFM eliminates the shear 












Figure 2.6 Schematic of Tapping Mode Scanning Force Microscope  
 In Tapping Mode SFM, as seen in Figure 2.6, a cantilever made of crystalline silicon 
oscillates at a resonant frequency and set amplitude. A red 632.8 nm laser beam is reflected off 
the backside of the cantilever to a mirror, which in turn directs the laser beam onto a split 
photodiode detector.  As the sample moves under the cantilever, the cantilever “taps” the 
surface on its downward position.  As the cantilever approaches the surface, the cantilever 
encounters several forces (Figure 2.7).  The forces used for detection in SFM are the van der 

















Figure 2.7 Observed Forces Between a Cantilever and a Sample Surface  
 
Any changes in the attractive or repulsive forces generated between the oscillating tip 
and the sample surface will change the frequency of the cantilever. The position of the laser 
upon the split photodiode detector changes due to this change. This change in position as a 
function of sample location is converted into an image such as height or amplitude.  Tip 
convolution is of concern as the objects may appear larger than their apparent sizes due to the 
probe’s inability to completely resolve the surface feature.9  
2.3.8 Tensiometry   
 Surface pressure measurements were conducted on solutions using the du Nuoy ring 
method on a Sigma 703 tensiometer.  A platinum ring of 5.992 cm mean circumference (CSC 
Scientific Company) was employed for the evaluation of no less than 500 µL of starting 
volume of each cyclic peptide.  The platinum ring was cleaned with a washing of absolute-200 
proof ethanol from Aaper followed by 18 MΩ deionized water.  An aliquot of the peptide 
solution was placed on a watch glass. The Pt ring was submerged in this aliquot and then 
removed repeatedly for 5 recordings of the surface pressure.  Additional aliquots of 18 MΩ 
10 µm Fluid Film Damping
1   µm Electrostatic Forces       (Attractive or Repulsive)
200 nm Fluid Surface Tension   (Attractive)
Å Van der Waals Forces   (Attractive)
< Å Coulombic Forces         (Repulsive)
Surface Plane
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water followed by agitation of the diluted solution upon the watchglass by pipettor allowed a 
range of concentrations to be studied. 
2.3.9 Theory of Tensiometry 
 The surface tension of a solution is determined by how extensive the cohesive forces 
between the molecules are.  In bulk solution, water can hydrogen bond in 4 positions, whereas 
at the surface, water molecules tend to place their hydrogen bonds closer to the hydrophobic air 
decreasing the amount of hydrogen bonding at the surface and thus causing excess energy for 
the molecule. This excess energy can be obtained by tensiometry where the excess free energy 
per unit area can be expressed as the force per length.   
There are two types of tensiometry methods available: Wilhelmy plate and du Nuoy 
Ring.  Most of the work done here was with the du-Nuoy ring setup where a platinum ring is 








Figure 2.8 Du-Nuoy Ring Setup 
 The surface tension, ST, measured by the Du-Nuoy ring method is determined by the 
outer diameter of the ring, d, and the thickness of the ring, t, in meters as seen in Equation 2.2. 
Equation 2.2 ST ring =            Force     
        (πd + π(d-2t)) 
Thus, the surface tension is based on the force per perimeter of the platinum ring.10   
Du-Nuoy Ring
Force just before film breakage
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2.3.10 Dynamic Light Scattering 
 Light scattering measurements were conducted on a home-built dynamic light scattering 
(DLS) instrument, using either a Lexel Ar+ laser operated at 488 or 514.5 wavelength (adequate 
for low light scattering levels), or a Pacific Instruments photometer/ pulse-amplifier-
discriminator, and a computer with an ALV-5000 multiple-τ digital auto correlator software 
version 5.11  The laser was directed into a vat containing the sample cell and a refractive index 
matching solvent, toluene n = 1.5. The scattered light was detected by a photomultiplier tube at 
some angle between about 15º or 150º.  The fluctuations of the intensities of the scattered light 











Figure 2.9 Schematic of DLS Apparatus 
2.3.11 Theory of Dynamic Light Scattering 
 Light scattering can be divided into two techniques: static which measures the time-
averaged intensities of light scattered from a solution of particles, and dynamic light scattering 









determinations of weight average molecular weight and radius of gyration, Rg, can be made. In 
dynamic light scattering, determinations of the hydrodynamic (Stokes) radius, Rh, of a 
scattering particle can be made.12  
  The scattering of light from a particle (molecule) is achieved after the polarization of 
this particle by incident light.11  In most instruments, this incident light, often from an Ar+ laser, 
is polarized perpendicular to the plane defined by the incident beam and the detector.11  When 
the polarized light impinges on a particle, both a parallel and perpendicular polarization to the 
incident light plane occurs.11  However, most dynamic light scattering studies only measure the 
scattering the polarized scattering.11   
The fluctuations of scattered light appear to be random and uncorrelated after long 
periods of time, but inspection of these fluctuations at very small time intervals reveals that 
they are correlated.  The persistence of the fluctuations can be described by an autocorrelation 
function.  Normalizing this autocorrelation function enables the expression of the electric-field 
autocorrelation function: 
Equation 2.3   g(1)(J) = exp(-Γt) 
 where the decay rate Γ may be thought of as the inverse of the duration of an average 
fluctuation event.  The diffusion coefficient or (speed) of the scatterer.  The translational 
diffusion coefficient, D, of the scatterer in medium is obtained from Equation 2.4: 
Equation 2.4   D =  Γ 
q2 
 where the scattering vector, q, is the measure of the spatial frequency of the light scattered at 
an angle θ, as expressed by Equation 2.5.12    
Equation 2.5   q =    4πno  sin (θ/2)    
                                                                        λo                  
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In Equation 2.5, the term n0, is the refractive index of the solution and λ0 is the wavelength of 
the scattered light in vacuo.  From this equation the hydrodynamic radius, Rh, of the scattering 
particle can be obtained by Equation 2.6. 
Equation 2.6   Rh =      kbT    
6πη D 
 
which is known as the Stokes-Einstein equation. The Boltzmann constant, kb, and solvent 
viscosity,0 at a specified temperature, T, are required to obtain Rh. 
 Estimation of this hydrodynamic radius can be obtained using the Equation 2.7, where 
Rh is the hydrodynamic radius, Mw is the molecular weight of the peptide, υ is the partial 
specific volume assumed to be 1.1 and NA is Avogadro’s number.13   
Equation 2.7   R h = 3 Mw υ  1/3 
          4π NA  
 
2.3.12 Reflection-Absorption Infrared Spectroscopy (RAIRS) 
 
 Reflection absorption infrared spectroscopy (RAIRS) was conducted on a Thermo 
Nicolet Nexus 670 Fourier transform infrared spectrometer using a liquid-nitrogen cooled, wide 
band MCT detector.  External reflection measurements were taken at 86º incidence using the 
Versatile Reflection Attachment with Retro-Mirror Accessory (Harrick, Ossining, NY).  
Corrections for H2O and CO2 were made prior to pristine HOPG background subtraction. A 
manual baseline was corrected for each spectrum. A 25 point smooth was performed by the 
vendor software (OMNIC 5.0).   
 2.3.13 Theory of Reflection-Absorption Infrared Spectroscopy 
 In RAIRS, incident infrared light impinges or and is reflected from a specular surface at 
equal angles (Figure 2.10).14  A specular surface displays a mirror like finish which has surface 
irregularities smaller than the wavelength of the incident IR light.14  If the irregularities in the 
material are larger than the wavelength of light, then scattering can occur.14  As the incident 
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light grazes the specular surface and also combines with the reflected light, a standing wave 
electric field is formed which can interact with the adsorbed species on the surface of the 
specular materials.14,15  
 Only parallel (p) polarized light can be absorbed by immobilized entities on the 
specular surface, and therefore an incident beam of parallel-polarized light at a near grazing 
angle is used.14,15  The reason for the use of parallel polarized light is due to vector addition; 
perpendicular (s) polarized light undergoes destructive interference of its electronic vectors 
upon reflection from a surface, and it is therefore not suitable for interacting with adsorbed 
species.15  It has been found that at an angle of incidence of 88º the reflectivity of light is 5000 
times more at an angle of 0º or normal.15 Thus, RAIRs is used to examine thin films containing 








Figure 2.10 Reflection-Absorption Infrared Spectroscopy 
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Chapter 3 
Organic-Solvent-Free Preparations of β-Amyloid and Amyloid-like Peptides: Scanning 
Force Microscopy Studies 
 
3.1  Introduction 
 Previous work by others has led to a basic understanding of the conditions needed to 
induce aggregation of various β-amyloid proteins in vitro.1,2  To better represent in vivo 
conditions, employed here is a completely aqueous pathway for the preparation of β-amyloid 
solutions for  in vitro studies.  Our route does not involve the use of organic co-solvents; such 
co-solvents were previously used to successfully dissolve and prepare a variety of Aβ peptides 
for solution–phase analysis.1,2An alternative route is to solubilize the Aβ material in aqueous 
hydroxide and then lyophilize in the resulting solution so as to yield the “sodium salt” of the Aβ 
peptide, which can be used to prepare aqueous stock solutions.3 
  The focus is on the preparation of stable aqueous solutions of Aβ and Amyloid-like 
peptides and the determination of the conditions that lead to reproducible aggregation of Aβ and 
Amyloid-like samples in an aqueous environment closely resembling physiological conditions. 
The work described here is of importance to research in the thesis topic of Aβ aggregation 
mediation by peptide mimics in aqueous environments.4-9 For reliable and reproducible 
observations regarding the effects of aggregation mediators to be achieved, stable solutions of 
Aβ or other Amyloid-like peptides containing no co-solvents are necessary. Finally, the method 
used for storage of aqueous Aβ solutions is shown to be of great importance, due to the 
observation that the nature of the interior of the polymer storage container can induce 
aggregation of otherwise stable aqueous Aβ solutions. 
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 In an effort to prepare aqueous solutions of varying concentrations of Aβ and Amyloid-
like peptides under a variety of solution conditions, it became necessary to make concentrated 
aqueous stock solutions of Aβ10–35,  Aβ1-40, and amylin20-29 free of organic solvents (such as 
dimethyl sulfoxide–DMSO). Although a previous report3 has briefly mentioned preparing such 
organic–solvent–free stock solutions of Aβ1–40 and another10 the formation of aqueous solutions 
from lyophilized “sodium salts” of Aβ1–40 and Aβ1–42, we found it necessary to fully investigate 
the nature of Aβ10–35, Aβ1-40, and amylin20-29  in high pH aqueous solutions due to possible 
differences in the aggregation behavior of the various fragments in aqueous media free of 
organic co-solvents.  
3.2       Behavior of Aβ10–35 in High pH, Low Ionic Strength Media and in Physiological pH,      
            Low Ionic Strength Buffer 
 
Shown in Figure 3.1 is a representative Tapping Mode SFM image obtained from a ~1 
mM Aβ10–35 pH 11 solution incubated at room temperature under N2 (to prevent pH drop due to 
CO2 absorption reaction) for 3 weeks. The only features visible are ~2.5–nanometer–tall globular 
structures of Aβ10–35; control experiments with Aβ–free buffers yielded featureless SFM images 
(bare mica). Although tip–sample convolution is a concern in imaging such small species, we 
report the length/width range of the globular deposits in Figure 3.1 to be 40 to 80 nm.11 There 
was no evidence for the presence of higher–order Aβ10–35 aggregates, as noted by the lack of any 
fibrillar species. These “non–aggregating” Aβ10–35 solutions can be maintained for 3 weeks, as 
long as pH is controlled; there is a need for a constant N2 atmosphere because the solution is 
unbuffered (roughly 10 mM KOH) and therefore greatly affected by CO2. Dynamic light 
scattering measurements of 300 µM Aβ10-35 in 10 mM KOH (pH 11) at 90º displayed a 
hydrodynamic radius of 3.2 ± 0.4 nm  during day one of sample preparation. 
 
 



















Figure 3.1 10 µm x 10 µm scanning force microscope image (on mica) obtained from a 
solution of 1 mM Aβ10–35 in 10 mM KOH. Image was obtained after sample had been 
incubated for 3 weeks at room temperature. The z-range is 10 nm. 
 
 In order to alleviate the need for a N2 atmosphere, we turned to making solutions of Aβ10–
35 in near physiological pH (~7.4) phosphate buffer. Upon addition of the necessary amounts of 
the 10 mM KOH solutions containing ~1 mM Aβ10–35 to “salt–free” phosphate buffer, stock 
solutions of Aβ10–35 that were pH stable over time could be prepared. 
  Shown in Figure 3.2 is a representative 10 µm x 10 µm SFM image of  300 µM Aβ10–35 in 
15 mM phosphate buffer solution; the solution was incubated at room temperature for a period of 
8 days prior to its contents being examined by SFM. Similar to the observations for the 10 mM 
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KOH solutions of Aβ10–35, no fibrillar species were observed in the SFM images, only small 0.8–





















Figure 3.2 10 µm x 10 µm scanning force microscope image (on mica) of 300 µM Aβ10–35 
that had been incubated at room temperature for 8 days in pH 7.64, 15 mM phosphate 
buffer (no salt added). The z-range is 10 nm. 
 
 The methods described here for preparing Aβ10–35 stock solutions under either the high 
pH or near physiological pH conditions lead to solutions that do not contain higher order 
aggregates.  As seen in Figures 3.1 and 3.2, the small peptide agglomerates do not appear to have 
any observable long-range order, as indicated by the lack of any fibrillar-like aggregates.  In 
addition, the size and number of the small peptide agglomerates did not change during the timed 
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incubation periods, pointing to a stable behavior for the stock Aβ10–35 solutions. Observation of 
the stable nature of the Aβ10–35 solutions under low ionic strength conditions in either high pH or 
near-physiological pH is important because reproducible studies of aggregation inhibition 
depend on the initial aggregate state of the Aβ material to be non-fibrillar (a seeding effect has 
been observed in other work12) and it must be the same for each preparation of stock Aβ 
solution.  In addition, the β-amyloid solution preparation protocols should be simple in nature.   
3.2.1 Preparation of β–Amyloid (1-40) Stock Solutions 
 Using the same protocol as that for Aβ10-35, stable solutions of Aβ1−40 were obtained by 
dissolving the solid peptide in 10 mM KOH solutions, as noted by Figure 3.3. The basic solution 
kept Aβ1-40 stable for 3 weeks with substantial aggregate growth only observed when the pH 
would drop. This pH drop is probably due to carbonic acid formation from repeated exposure to 
air.  Also, the solution’s stability may have been compromised by dust contamination during the 
retrieval of aliquots for sample preparations. Attempts to directly prepare Aβ1-40 stock solutions 
from solid peptide containing phosphate buffer in the absence or presence of added salt (ionic 
strength) resulted in rapid aggregation. This aggregation was apparent in minutes by visual 
observation of Aβ1-40 precipitation in the microcentrifuge tube. Thus, no filtering could be 
accomplished to salvage any soluble Aβ1-40, as this aggregated material clogged the 0.02 µm 
Anotop filter, indicated by high syringe back pressure.  The remaining aggregated material in the 
syringe was taken out and placed on mica for SFM analysis as seen in Figure 3.4.  Scanning 
force microscopy analysis of this aggregated solution yielded micrographs displaying noted areas 
















































Figure 3.3 15 µm x 15 µm scanning force microscope image (on mica) of filtered 500 µM 
Aβ1-40 adsorbed on mica after 5 weeks. Lyophilized peptide was dissolved in 10 mM KOH 
at pH 10, filtered with 0.02 µm Anotop filter and stored at 8 ºC. Aggregate height ranged 
from 2 to 12 nm. The z–range is 10 nm. 
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Figure 3.4 10 µm x 10 µm scanning force microscope images (on mica) of unfiltered 500 µM 
Aβ1-40 adsorbed on mica immediately after preparation. (A) Lyophilized peptide was 
dissolved directly in 50 mM phosphate buffer at pH 7.4; abundant aggregate height ranged 
from 5 to 24 nm. (B) Lyophilized peptide was dissolved in 50 mM phosphate buffer and 150 
mM NaCl at pH 7.4; abundant aggregate height ranged from 5 to 13 nm. The z–range is 10 
nm. 
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3.2.2 Aqueous Preparations of Amylin Peptide  
 The specificity of the peptide-based mediators with respect to Aβ aggregation  required 
the use of amyloid like peptides that form fibrils.  Amylin20-29 was used for these specificity 
studies because it has been found to form amyloid-like fibrils, and it does not have the disulfide 
bridge contained in full-length amylin1-37.  Amylin1-37 (formula weight 3903 g/mol) has sulfides 
originating from two cysteines on residues 2 and 7 in the sequence; this disulfide bridge is 
thought to have caused the rapid aggregation observed in these studies when this peptide was 
dissolved in 10 mM KOH.  It has been observed that after 9 days at 8 ºC in pH 11.5 10 mM 
KOH, amylin20-29 readily aggregates.  These aggregates were non–fibrillar in nature, but were 
large asymmetrical agglomerations greater than 150 nm in height; such large aggregations were 
difficult to resolve with SFM.  Thus, the stability of stock solutions of amylin20-29 was lower than 
Aβ stock solutions, but it was still suitable for the specificity studies. 
3.2.3  Effect of Sample Storage Containers on Aggregation Behavior of Aβ10–35  
 
 A key issue in the evaluation of mediators for the aggregation of Aβ peptides was the 
ability to reproducibly prepare stable solutions of the Aβ peptides in aqueous media free of 
influencing factors.  In addition, controlled initiation of Aβ aggregation was necessary for such 
mediator studies. Once these two conditions were satisfied, successful studies were then 
completed regarding the possible effects of mediators on the aggregation of Aβ materials. 
From the study of sample containment in two different types of poly(propylene) vials 
presented here, it is clear that surface-induced aggregation of Aβ10–35 is a key issue that must be 
addressed when using Aβ materials.  Previous work by others indicates that the hydrophobicity 
and chemical nature of a surface can influence the aggregation behavior of Aβ materials.13 The 
SFM and XPS data presented here clearly demonstrate that chemically identical but 
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microscopically rough surfaces can significantly alter the kinetics, and most likely the pathway, 
of Aβ10–35 aggregation in aqueous media.  
 The X–ray photoelectron spectroscopy (XPS) data were obtained with a Kratos AXIS 
165 X-ray spectrometer. The samples were prepared for analysis by cutting a small sliver of the 
wall of both the Dot Scientific and Sarstedt microtubes with a clean razor blade. The inner walls 
of the microtubes were positioned upward for exposure and both were clamped onto the same 
sample plate for analysis. An aluminum anode was used to produce the monochromatic K alpha 
X–rays. The presence of no other elements besides carbon on the surface of the poly(propylene) 
vials, Figure 3.5, as judged by XPS points to another surface characteristic influencing the 
aggregation of Aβ10–35. We attribute the more rapid aggregation of Aβ10–35 in the Sarstedt tubes 
to their three-fold higher interior surface roughness (RMS roughness of 19.7 nm) versus the Dot 
Scientific microcentrifuge tubes (RMS roughness of 5.8 nm) as seen in Figure 3.6. 
Results from a recent scanning force microscopy study of Aβ1–42 are suggestive of 
increased aggregation on nanoscopically rough surfaces.12 We conclude that the rougher 
poly(propylene) surfaces act as nucleation sites for the Aβ10–35, which lead to production of 
structured Aβ10–35 seeds, which in turn cause aggregation of solution-phase Aβ10–35.  
 The presence of seeds in solution has been shown to greatly accelerate the rate of Aβ 
aggregation.14  Similar effects to those observed here for Aβ10–35, have been found with Aβ1–40, 
and research conducted by students under the direction of Dr. Robin McCarley at Louisiana State 
University is currently exploring the role of surface chemistry and roughness in the aggregation 
pathway of various Aβ materials in aqueous solution.  
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Figure 3.5 X-ray photoelectron survey spectrum of interior of Dot Scientific and Sarstedt 
microcentrifuge tubes.  No impurities (such as metals or surfactants) are evident as noted 









































Figure 3.6 10 µm x 10 µm scanning force microscope image of inner wall of 
microcentrifuge tube: (A) Dot Scientific, RMS roughness = 5.8 nm and (B) Sarstedt, RMS 
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 Other influencing factors in the aggregation of Aβ peptides include the presence of non-
Aβ seeds (heterogeneous nucleation) and metal ions.  These potential aggregation facilitators can 
speed an otherwise slow nucleation and growth process. For example, we have noted that when 
solutions of Aβ10–35, or the solutions used to dissolve the peptide, are not filtered through the 
0.02 µm filters, aggregation occurs very rapidly and in an uncontrolled manner.  SFM and light 
scattering experiments point to the presence of dust particles in these solutions as aggregation 
accelerants, further confirmed by  a previous study.15   In addition, the use of high-purity 
materials for solution preparations so as to prevent metal ion or surfactant impurities is of great 
importance, and we have followed such a stringent protocol here. 
3.2.4 Behavior of Aβ10–35 and Aβ1-40 in Physiological pH, High Ionic Strength Buffer 
 
 Amyloid β−peptides have previously been shown to aggregate more quickly in aqueous 
solutions containing salts, although the impact of the presence of organic co–solvents on this 
aggregation behavior is not known.10 We report here the addition of salts to aqueous solutions of 
Aβ10–35 and Aβ1-40 peptides containing no organic solvents. 
 In initial Aβ aggregation studies, Aβ10–35 were prepared in pH 7.5 phosphate buffer 
containing fixed concentrations of NaX salts: (X= Cl, F, and NO3) and then examined their 
contents as a function of time using SFM. Shown in Figure 3.7 is a representative 10 µm x 10 
µm Tapping Mode SFM image of 300 µM Aβ10–35 in 15 mM phosphate buffer containing 50 mM 
NaCl incubated at room temperature for 8 days and then exposed to mica. Examination of Figure 
3.7 (and other aliquots obtained from similarly prepared solutions) led to observation of fibrillar 
Aβ10–35 structures varying in length from 40 nm to 1.2 µm and 7-12 nm in height. Such long 
Aβ10–35 fibrils were also observed when 50 mM NaF was present in the 300 µM Aβ10–35 15 mM 
 
  64 
 
phosphate buffer solutions. Roughly 6–nm–tall, 600 nm to 3 µm long fibrils were observed when 


























Figure 3.7 10 µm x 10 µm scanning force microscope images (on mica) of 300 µM Aβ10–35 
incubated for 8 days at room temperature in 15 mM phosphate buffer containing 50 mM 
(A) NaCl at pH 7.77, (B) NaF at pH 7.75, and (C) NaNO3 at pH 7.67. The z-range is 20 nm 
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 In contrast to the cases for NaCl and NaF, no observable fibrils were found upon SFM 
inspection of mica surfaces exposed to 300 µM Aβ10–35 solutions in 15 mM phosphate buffer 
containing 50 mM NaNO3. Only 6–18 nm–tall spherical aggregates were found in SFM images 
obtained from such Aβ10–35 solutions containing NaNO3, as seen in Figure 3.7C. In general, high 
ionic strength environments led to formation of fibrillar aggregates or large agglomerates of 
Aβ10–35 in aqueous buffer solutions containing no organic co-solvents. This was evidenced by the 
presence of micrometer-long fibrils in the SFM images of Aβ10–35 solutions spotted on mica after 
incubation under buffered conditions when either 50 mM NaCl or NaF are present.  Although no 
fibrils were produced during the 8-day incubation period when NaNO3 was used to increase the 
ionic strength, there were much larger number of peptide agglomerates that are much larger (2–
20 times) than when no salt was present—compare Figures 3.2 and 3.7 C.  At this time, it is 
unclear why this difference exists when nitrate is used versus chloride or fluoride, but it is 
possible that it is caused by interactions between the nitrate anion and the salt bridge of the full 
length Aβ.  The cross β motif of the full length Aβ contains a salt-bridge between the 23rd 
residue, the negatively charged aspartate amino acid, and the 28th residue, the positively charged 
lysine amino acid.  It is possible, that the nitrate anion may interact with this salt-bridge and thus 
keep the bridge from completion.  This interference could keep the cross β motif (Figure 1.5) 
from forming and thus inhibit fibril development. 
 Aβ fibrillar structures have also been observed for Aβ1–40 prepared within phosphate 
buffered saline solutions (Figure 3.8).  Thus, the sample preparation protocol allows the 















Figure 3.8 10 µm x 10 µm scanning force microscope image (on mica) of 50 µM Aβ1–40 
incubated for 8 days at room temperature in 50 mM phosphate buffer containing 150 mM 
NaCl at pH 7.4.  Fibrils were 1-3 µm in length and 6-7 nm in height.  
 
3. 3 Conclusion 
 It has been demonstrated that the reproducible preparation of organic-solvent-free 
aqueous solutions of Aβ10−35  and Aβ1−40  do not result in Aβ higher-order aggregation for 
extended periods of time.  Key to the successful preparation of these stable, concentrated 
Aβ10−35  and Aβ1−40  solutions is the removal of possible nucleation seeds (either Aβ or dust), 
exclusion of impurities during solution preparation, and careful consideration of the nature of the 
solution storage containers.  In addition, it has been shown that formation of Aβ10−35  and Aβ1−40  
fibrils and large aggregates can be triggered by addition of a variety of salts to these otherwise 
non-aggregating Aβ solutions.  The nitrate anion may prevent the initial formation of the β-sheet 
rich Aβ aggregate, which enables Aβ fibril development, by sustaining a random coil or alpha 
helical Aβ conformer by interaction with the positively charged amino acid lysine utilized in the 
salt-bridge of Aβ1-40.  
 
  67 
 
3. 4 References 
 
(1) Stine, W. B., Jr.; Snyder, S. W.; Ladror, U. S.; Wade, W. S.; Miller, M. F.; Perun, T. J.; 
Holzman, T. F.; Krafft, G. A. The nanometer-scale structure of amyloid-beta visualized 
by atomic force microscopy. Journal of Protein Chemistry 1996, 15, 193-203. 
 
(2) Harper, J. D.; Wong, S. S.; Lieber, C. M.; Lansbury, P. T., Jr. Observation of metastable 
beta amyloid protofibrils by atomic force microscopy. Chemistry & Biology 1997, 4, 119-
125. 
 
(3) Fezoui, Y.; Hartley, D. M.; Harper, J. D.; Khurana, R.; Walsh, D. M.; Condron, M. M.; 
Selkoe, D. J.; Lansbury, P. T.; Fink, A. L.; Teplow, D. B. An improved method of 
preparing the amyloid beta-protein for fibrillogenesis and neurotoxicity experiments. 
Amyloid-International Journal of Experimental and Clinical Investigation 2000, 7, 166-
178. 
 
(4) Soto, C. Alzheimer's and prion disease as disorders of protein conformation: implications 
for the design of novel therapeutic approaches. Journal of Molecular Medicine 1999, 77, 
412-418. 
 
(5) Ghanta, J.; Shen, C.-L.; Kiessling, L. L.; Murphy, R. M. A strategy for designing 
inhibitors of beta-amyloid toxicity. Journal of Biological Chemistry 1996, 271, 29525-
29528. 
 
(6) Hughes, E.; Burke, R. M.; Doig, A. J. Inhibition of toxicity in the beta-amyloid peptide 
fragment beta-(25-35) using N-methylated derivatives: a general strategy to prevent 
amyloid formation. Journal of Biological Chemistry 2000, 275, 25109-25115. 
 
(7) Soto, C.; Kindy, M. S.; Baumann, M.; Frangione, B. Inhibition of Alzheimer's 
amyloidosis by peptides that prevent beta-sheet conformation. Biochemical and 
Biophysical Research Communications 1996, 226, 672-680. 
 
(8) Lowe, T. L.; Strzelec, A.; Kiessling, L. L.; Murphy, R. M. Structure-Function 
Relationships for Inhibitors of beta-Amyloid Toxicity Containing the Recognition 
Sequence KLVFF. Biochemistry 2001, 40, 7882-7889. 
 
(9) Gordon, D. J.; Meredith, S. C. Probing the role of backbone hydrogen bonding in beta-
amyloid fibrils with inhibitor peptides containing ester bonds at alternate positions. 
Biochemistry 2003, 42, 475-485. 
 
(10) Harper, J. D.; Wong, S. S.; Lieber, C. M.; Lansbury, P. T., Jr. Assembly of A beta 
amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. 
Biochemistry 1999, 38, 8972-8980. 
 
(11) Tegenfeldt, J. O.; Montelius, L. Image widening not only a question of tip sample 
convolution. Appl. Phys. Lett. 1995, 66, 1068-1070. 
 
 
  68 
 
(12) Harper, J. D.; Lieber, C. M.; Lansbury, P. T., Jr. Atomic force microscopic imaging of 
seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta 
protein. Chemistry and Biology 1997, 4, 951-959. 
 
(13) Kowalewski, T.; Holtzman, D. M. In situ atomic force microscopy study of Alzheimer's 
beta-amyloid peptide on different substrates: new insights into mechanism of beta-sheet 
formation. Proceedings of the National Academy of Sciences of the United States of 
America 1999, 96, 3688-3693. 
 
(14) Matsuzaki, K.; Horikiri, C. Interactions of amyloid beta-peptide (1-40) with ganglioside- 
containing membranes. Biochemistry 1999, 38, 4137-4142. 
 
(15) Lomakin, A.; Chung, D. S.; Benedek, G. B.; Kirschner, D. A.; Teplow, D. B. On the 
nucleation and growth of amyloid .beta.-protein fibrils: detection of nuclei and 
quantitation of rate constants. Proceedings of the National Academy of Sciences of the 





Characterization of Aβ Aggregation Mediators 
 
 
4.1       Designing Peptide-Based Aggregation Mediators 
 The proposal of using aggregation mediating peptides to eliminate the toxic aggregate 
pathway of β-amyloid has been supported by the observation that diffuse plaques of β-amyloid 
do not affect surrounding neurons or activate glial cells.1  Therefore, peptide-based aggregation 
mediators can be designed with the intent to cause aggregation of β-amyloid into a non-toxic 
species.  The proposed mediators in this work are based on an amino acid sequence known to 
cause β-amyloid fibril formation.2,3  The binding affinity of this segment, KLVFF, of amino 
acids 16-22 in the full length sequence of β-amyloid, has been shown to bind specifically to 
much larger Aβ10-35 materials and also was beneficial in reducing cellular toxicity caused by the 
presence of β-amyloid.4  Therefore, peptides containing this amino acid sequence have been 
proposed as viable mediators of β-amyloid aggregation. 
 The Aβ aggregation  mediators developed at Louisiana State University contain Cα,α 
disubstituted amino acids within this KLVFF sequence as seen in Figure 4.1.5,6  The alternating 
substitution of the KLVFF region with Cα,α disubstituted amino acids was designed to create an 
extended conformation of the mediator.5,6  The extended conformation enables the mediator to 
display β-stand conformation properties.  This conformation allows possible β-strand interactions 








                      

































Figure 4.1 Peptide–Based Aggregation Mediators. (A) Peptide aggregation mediator 
developed by Dr. Regina Murphy at the University of Wisconsin. (B) Mediators developed 
by Dr. Robert Hammer; mediators were defined by their lysine number and positions: 
AMY-1  x = 1, y = 6 ; AMY-2  x = 6, y = 1 ; AMY-3  x = 1, y = 1.  The chemdraw drawings 
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4.1.1 Peptide-Based Aggregation Mediator Studied 
The peptide-based aggregation mediator developed by Dr. Regina Murphy at the 
University of Wisconsin with a  molecular weight of 1420.9 g/mol contained the KLVFF region 
of β-amyloid and an oligolysine tail at its C-terminus to allow higher solubility.  Two other 
mediators, AMY-1 and AMY-2, were developed by Dr. Robert Hammer and synthesized by Dr. 
Yanwen Fu and Marcus Etienne with a molecular weight of 1708 g/mol.  Both AMY-1 and 
AMY-2 mediators contained a portion of the hydrophobic KLVFFAED region located in β-
amyloid, but had substitutions of dibutylglycine (DIBG) for leucine (L), dibenzylgylcine 
(DBZG) for phenylalanine (F) and a dipropylglycine (DPG) for an alanine (A).  The differences 
between AMY-1 and AMY-2 lay in the position of the oligolysine tail; AMY-1 has the 6 lysines 
on its C-terminus, while, AMY-2 has its 6 lysines on its N-terminus.  
4.1.2    Assessment of Possible Self-Aggregating Behavior of Inhibitors 
Scanning force microscopy was used to note any apparent self-aggregation of the 
peptide-based mediators, as outlined in Figure 4.2.  It was found that AMY-2 readily self-
aggregates, as indicated by observation of apparent monolayers on mica 1.3 ± 0.1 nm in height.  
AMY-1 had aggregates in the range of 1 to 17 nm in height, whereas the mediator created by Dr. 
Regina Murphy resulted in aggregates that are 1-8 nm in height. 
4.1.3    Assessment of Surface-Active Properties of Peptide-Based Aggregation Mediators 
 
The surface active properties of each peptide-based aggregation mediator were examined 
to determine whether each mediator had any surfactant-like properties, Figure 4.3.  Due to an 
observed drop in surface tension around 1mM, both AMY-1 and AMY-2 mediators probably 
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Figure 4.2 10 µm x 10 µm SFM images of 50 µM mediators in 50 mM phosphate/150 mM 
NaCl at pH 7.4. (A) AMY-1, (B) AMY-2, (C) Murphy.  Samples were incubated at room 
temperature after an initial incubation at 37 °C for 1.5 hours. White bar is 1 µm in length. 
Z-range is 20 nm. 
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 The small volumes used (200 µL) to reduce sample consumption, and the 25 mm 
diameter watch glass to enable immersion of the du-Nuoy ring demonstrated a surface tension of 
water to be 83.1 ± 1.  This value was much larger than the 72.5 ± 0.5 surface tension of water 
found at a volume of 400 µL of water in a 50 mm watch glass.  Therefore, Figure 4.3 had high 
trend values for surface activity due to the nature of sample reduction.  Still, the effort proves 
that surface activity occurs with increasing AMY-1 and AMY-2 concentration and concentration 
has no effect for the inhibitor developed by Dr. Regina Murphy.  Other experiments for 
determining surface activity were mainly with peptide based aggregation solutions of 
concentrations at 50 µM and with volumes at 1000 µL allowing measurements with the large 50 
mm watch glass. 
The mediator developed by Dr. Regina Murphy did not display any apparent change in 
surface activity over the concentration range studied; this inhibitor was found by Dr. Regina 
Murphy’s group to increase the surface tension of solutions.7   The CMC of each mediator 
increased our understanding of the role of each mediator when in an environment of β-amyloid 
peptide.  The 1 mM CMC value of AMY-1 and AMY-2 is 20 fold larger than the concentrations 
of these inhibitors used in the aggregation inhibition/mediation studies in Chapter 6.  Therefore, 
interaction of AMY-1 and AMY-2 at the intended concentrations with β-amyloid should involve  
specific interactions instead of the presence of secondary structure stabilizing micelles, such as 
has been found for Aβ1-40 in a sodium dodecyl sulfate (SDS) micellar environment.8,9 
4.1.4 Conclusion 
 
The surface activity of each peptide-based aggregation mediator was investigated to 


















Figure 4.3 Plot of Surface Pressure Measurements of Peptide-Based Aggregation 
Mediators.  Measurements for AMY-1 were obtained in pH 11, 10 mM KOH; AMY-2 in 
pH 4.7, deionized 18 MΩ water; and Murphy in pH 4.5, deionized 18 MΩ water. 
 
 
monomeric state and not interacting with a possible micellar form of the mediators.  It was found 
that at the concentrations of inhibitors used in the Aβ aggregation mediation studies (Chapter 6) 
there were no micellar species present.  Also, SFM analysis of each mediator alone allowed any 
observation of inhibitor self-aggregating ability.  It was found that AMY-2 favored monolayer 
adsorption on mica, whereas AMY-1 and the mediator developed by Dr. Regina Murphy 
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Properties of β-Amyloid at the Air/Water Interface in the Presence or Absence of 
Aggregation Mediators 
 
5.1 Background on Surface Activity of Amyloid-Containing Solutions and Stabilization  
of Aβ Aggregates by Surfactants 
 
 Aβ protein fragments resemble amphipathic surfactants owing to their composition of 
both a polar N-termini and a hydrophobic C-termini; fragments of β-amyloid from Aβ1-33 to Aβ1-
43 have been noted to be surface active with an average critical micelle concentration around 25 
µm.1  Aβ1-40 has been found to fold into a β sheet conformation at the air-water interface.2  
Studies of β-amyloid under acidic conditions yielded an observation of spherocylindrical micelle 
structures with a length of 11 nm and a width of 4.8 nm (containing 30-50 Aβ monomers).3  
 The addition of the surfactant sodium dodecyl sulphate (SDS), above its critical micelle 
concentration, to solutions of  β-amyloid has led to stabilization of the amyloid protein as an α-
helical structure.4  Below the critical micelle concentration of SDS, Aβ forms fibrils as a result of 
rapid conversion of initially α-helical conformations to β-sheet structures.5  
5.2 Surface Activity of β-Amyloid in the Presence and Absence of Mediators 
 The surface activities of β-amyloid solutions containing peptide based aggregation 
mediators were assessed.  The surface tension of H2O is 72 mN/m.  The surface tension of Aβ1-40 
at 50 µM is substantially lower than each one of the mediators studied individually (Figure 5.1).  
However, the introduction of AMY-1 or AMY-2 additionally lowered the surface tension of β-
amyloid, whereas the Murphy inhibitor increased the surface tension of the solution.6 This 
increase in the surface tension of Aβ1-40 solutions by the Murphy inhibitor has been reported by 
Dr. Regina Murphy and is thought to aid in increasing the rate of Aβ1-40 aggregation.6   
 The surface tension of the peptide, Aβ25-35, which does not contain the KLVFF sequence, 
did not display any surface activity alone.  Again, AMY-1 and AMY-2 lowered the surface 
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tension of this peptide, but the surface tension was not affected by the presence of the Murphy 
inhibitor (Figure 5.2 A). The lowering of Aβ25-35 was probably due to the stronger surfactant 
activity of AMY-1, because the surface tension was close to AMY-1 alone.  AMY-2 lowered the 
surface tension of Aβ25-35 below that of AMY-2 alone.  AMY-2 therefore lowers the surface 
tension of both Aβ1-40 and Aβ25-35 solutions below the value of AMY-2 solutions at 50 µM.  
 A similar effect was observed with amylin20-29.  Again, addition of AMY-1 and AMY-2 
to amylin solutions lowered the surface tension slightly, with Murphy having no effect (Figure 
5.2 B).  AMY-1 or Murphy did not drop amylin20-29 lower than their own individual surface 
tensions, but addition of AMY-2 to amylin20-29 solutions lowered the surface tension a 
considerable amount.     
5.3      Conclusion 
 
A binary mixture of surface-active agents can complex and form a compound with even 
higher surface activity than the agents alone (Figure 5.3).6  This was observed in the case of 
AMY-2 with Aβ1-40, Aβ25-35, and amylin20-29.  AMY-2 formed a complex which each fibril 
forming peptide having greater surface activity than AMY-2 or each fibril forming peptide 
would have alone.  However, AMY-1 was more selective and only complexes with Aβ1-40 to 
form a more surface-active complex.  The mediator developed by Dr. Regina Murphy increased 
the surface tension of Aβ1-40 only, had no effect on Aβ25-35,  and moderately lowered the surface 
tension of amylin20-29.  Therefore, AMY-1 displayed some selectivity in complex formation with 
Aβ1-40 due to the observation that AMY-1 surface tension dropped when only in the presence of 
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Figure 5.1 Surface pressure measurements of mediators alone (A) and in the presence of 























Mediators in the Absence of other Proteins





























































Figure 5.2  Surface pressure measurements of Aβ25-35 (A) and amylin20-29 (B) in the 
presence or absence of mediators. 
 
 


















Amylin in the Presence or Absence of Mediators
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Figure 5.3 Representation of how individual fibril-forming peptides (A) and mediators (B) 
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 Chapter 6 
Mediation of Aβ Aggregation  
 
6.1 Initial Aggregation Mediation Studies 
 Research was initially conducted on understanding the aggregation of Aβ10-35 due to its 
slower aggregation rate than the larger β-amyloid peptides Aβ1-40 and Aβ1-42. This peptide still 
contained the necessary amino acids, namely those in the hydrophobic and the β-turn regions of 
the full-length complement. Aβ10-35 was used for my early investigations of the first available 
peptide-based aggregation mediator, AMY-1 developed at Louisiana State University.  AMY-1 
was found to inhibit fibril formation of Aβ10-35 and form spherical agglomerates of various sizes.  
6.1.1 Studies of AMY-1 Inhibitor in the Presence of Aβ10-35 
 It was determined that at a ratio of 9:1 of AMY-1 to Aβ10-35, significant differences in 
aggregation were observed when compared to a control of only Aβ10-35 (Figure 6.1). This control 
was a 50 µM Aβ10-35 sample in 15 mM phosphate buffer and 150 mM NaCl at pH 7.3. This 
sample was incubated at 37 ºC for 14 hours and was maintained at a pH of 7.3, until an aliquot 
was spotted onto mica and subsequently imaged by Tapping mode SFM.  Images obtained from 
an aliquot of the control displayed an extensive network of 560 µm to 700 µm long fibrils having 
heights 2-28 nm. This fibril formation was not present in the sample containing the AMY-1 
mediator. The sample with the 9:1 AMY-1 mediator to Aβ10-35 ratio experienced the same 
conditions as the control. An SFM image obtained from the 9:1 sample at the same time point as 
the control exhibited only very small spherical aggregates that were on average 61.8 ± 2 nm wide 
and 2.1 ± 0.8 nm tall.  Interestingly, the differences between the sample without the AMY-1 
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mediator and with mediator are quite striking, as noted by the lack of fibrils or large 






     
     
 



















Figure 6.1 10 µm x 10 µm SFM images on mica showing: (A) 50 µM Aβ10-35 with fibrils 560 
µm and 700 µm in length with a height range of 2-28 nm, (B) 9:1, 450 µM AMY-1 to 50 µM 
Aβ10-35, average aggregate is 61.8 ± 2 nm in width and 2.1 ±  0.8 nm in height.  The z-range 
is 10 nm. Solution conditions were 15 mM phosphate buffer and 150 mM NaCl at pH 7.3. 
This sample was incubated at 37 ºC for 14 hours. 
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 The images shown here are representative of 5 replicate measurements (images) obtained 
and all images yielded similar features with and without the AMY-1 inhibitor.  AMY-1 was 
found to inhibit amyloid fibril formation at a 1:1 ratio of mediator to Aβ10-35 in an environment of 
18 mM phosphate buffer at an ionic strength of 116 mM NaCl at pH 7.4. This sample was 
observed over a period of 9 days with the last time point displayed in Figure 6.2. The control, 
300 µM Aβ10-35, exhibited  large 1.5-µm wide and 143-nm tall aggregates. These large structures 
were not seen in the samples containing AMY-1. Apparent changes in the mechanism of 
aggregate formation were observed with the introduction of AMY-1. The 1:1 AMY-1:Aβ10-35 
sample exhibited an average particle width of 193 ± 52 nm and height of 15 ± 3 nm. Under 
identical conditions, a 3:1 ratio of AMY-1 to Aβ10-35 led to the observation of particles that are a 
bit larger, with 305 ± 26 nm wide and 49 ± 6 nm tall species observed. 
6.2 Aggregation Mediation Studies with Aβ1-40  
 In order to investigate the general efficacy of the AMY mediator series, a more extensive 
comparison study was undertaken with Aβ1-40.  The Aβ1-40 peptide is more relevant to in vivo 
work due to its more rapid aggregation under physiological buffer conditions.  Mediator efficacy 
studies involved observing any possible aggregates formed by Aβ1-40 in the presence and the 
absence of each mediator (AMY-1, AMY-2, and Murphy inhibitor).  After incubation at 37 ºC 
for 1.5 hours, Aβ1-40 alone displayed an abundance of spherical aggregates (> an estimated  
thousand in field of view), and were around 3 nm in height with more linear-like aggregates 
which were 140-470 nm in length comprised of the spherical aggregates.  These early “pearl 
like” structures have been identified elsewhere as the precursor (protofibril) of the much larger β-
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Figure 6.2 10 µm x 10 µm SFM images on mica showing: (A) 300 µM Aβ10-35, (B) 1:1 300 
µM AMY-1/300 µM Aβ10-35 at pH 7.7. Solution conditions were 18 mM phosphate buffer at 
an ionic strength of 116 mM NaCl at pH 7.4. The image shown here was taken after 9 days 
at room temperature. Z-range was 300 nm.   
 
 
 Initial visual observation of the AMY-2 interaction with Aβ1-40 provided a unique 
appearance of rapid aggregation in solution.  When AMY-2 was added to Aβ1-40 solutions at a 
1:1 ratio (50 µM each), the solution rapidly became opaque and took on a colloidal appearance 
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(30 minutes).  Such rapid aggregation was not observed when either Aβ1-40 or AMY-2 was alone 
under the same conditions and identical times.  
  A scanning force microscopy image further details the extent of AMY-2 interaction with 
Aβ1-40 after a 1.5 hour incubation at 37 ºC.  SFM images from a 1:1 AMY-2:Aβ1-40 ratio 
displayed large amorphous aggregates which are assumed to be of the β-amyloid and AMY-2 
interaction product.  These non-fibrillar aggregates were measured to be 70-117 nm in height and 
were clustered together.  Both AMY-1 and Murphy mediation of Aβ1-40 aggregation displayed 
aggregated material without the “pearl-like” spherical aggregates (protofibrils) observed in the 
Aβ1-40 alone solutions. 
 A second study designed to explore the later stages of Aβ1-40 aggregation to form higher-
order aggregates (fibrils) was performed. Images of 50 µM Aβ1-40 alone, pointed out the presence 
of elongated fibrils greater than 10 µm in length and roughly 8 nm in height Figure 6.4A.  This 
sample, after an incubation at 50 ºC for 1.5 hours, exhibited no fibrils, but rather a small number 
of amorphous aggregates of varying height (3-9 nm). Along with these small amorphous 
aggregates, a monolayer of adsorbed material (0.5 nm in height) was observed and probably 
contributed by the product.  It is important to note that the sample of the AMY-2:Aβ1-40 was 
taken from the middle of the microcentrifuge tube; it was apparent that the majority of the 
material had settled to the bottom of the storage container.  Samples from the 1:1 AMY-1 and 
Aβ1-40 solution had aggregates 8-17 nm in height, as well as a layer of adsorbed material (0.6 nm 
in height), as seen in Figure 6.4B.  However, as noted in Figure 6.4D, a fibrillar structure (696 
nm in length) and aggregates 3-7 nm in height from the sample containing 1:1 of Dr. Regina 
Murphy’s peptide and Aβ1-40.  
 Transmission electron microscopy work on Aβ1-40 after one week at room temperature in 
50 mM phosphate buffer and 150 mM NaCl at pH 7.4 resulted in significant fibril formation 
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(Figure 6.5A).  At a ratio of 1:1 AMY-1 to Aβ1-40, also in 50 mM phosphate buffer and 150 mM 
NaCl at pH 7.4, only amorphous agglomerates were observed (Figure 6.5B) similar to the 
aggregates seen in Figure 6.2B.  The aggregation mediation of Aβ1-40 by AMY-2 under identical 
conditions also encompasses the formation of non-fibrillar aggregates.  The inhibitor developed 
by Dr. Regina Murphy resulted in slightly larger aggregates, but were also amorphous in nature 
(Figure 6.5 C, D). 
6.3 Overall Observation of Aggregation Mediator Efficacy  
 Measurements of the surface activity by tensiometry of each mediator alone have 
revealed that each of these mediators displayed no micelle formation at the concentrations used 
in our studies (50 µM).  Dr. Regina Murphy at the University of Wisconsin has reported that the 
inhibitor, KLVFF(K)6, increases the surface tension of Aβ1-40 containing solutions; this 
observation was also found in our work detailed in Chapter 5, Figure 5.1B.1 Dr. Regina 
Murphy’s group believed that the increased rate of Aβ aggregation was caused by this increase in 
surface tension, but also found that increases in surface tension alone did not increase Aβ1-40 
aggregation.1  This increased rate of aggregation was also found at Louisiana State University by 
dynamic light scattering as a 276 nm aggregate of 1:1 Aβ1-40 :Murphy grew into a larger 712 nm 
aggregate after 1.5 hours at 40º C.  
 An increased rate of Aβ aggregation was also identified with the AMY-2 mediator 
developed at Louisiana State University.  AMY-2 increases the rate of Aβ aggregation but 
decreases the surface tension.  There must be another mechanism such as complex formations 
between Aβ and mediators which can change the surface tension of the Aβ containing solution 
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Figure 6.3 5 µm x 5 µm SFM images on mica demonstrate aggregation mediation of Aβ1-40 
at 50 µM with added mediators and an inhibitor.  (A) Small precursor aggregates and 
protofibrils were observed for 50 µM Aβ1-40. (B) 1:1 AMY-1:Aβ1-40. (C) Large amorphous 
aggregates of 1:1 (Aβ1-40 : AMY-2). (D) 1:1 Murphy and Aβ1-40.  Samples were incubated at 
37 ºC for 1.5 hours. Solution conditions were 50 mM phosphate and 150 mM NaCl. pH of 
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Figure 6.4 5 µm x 5 µm SFM images on mica obtained from solutions of Aβ1-40 in the 
presence and absence of peptide-based aggregation mediators.  Samples were incubated at 
50 ºC for 1.5 hrs in 50 mM phosphate buffer and 150 mM NaCl. (A) 50 µM Aβ1-40 alone; 
(B) 1:1 with AMY-1; (C) 1:1 with AMY-2; (D) 1:1 with Murphy inhibitor. White bar is 1 








































Figure 6.5 Transmission electron micrographs of 50 µM Aβ1-40 in the presence or absence 
of peptide-based aggregation mediators. (A) Aβ1-40 alone, (B) 1:1 with AMY-1, (C) 1:1 with 
AMY-2, (D) 1:1 with Murphy after 9 days at room temperature in 50 mM phosphate and 
150 mM NaCl at pH 7.4. 
 
 
 Even though the mediators at the concentrations studied (50 µM) do not form micelles, 
there is reason to believe that indeed micelles are a part of these studies; Aβ1-40 has a micelle 
concentration at 25 µM.2   Therefore, interactions between each mediator in the bulk of the 
solution may involve a capping of, intercalation of the core, or insertion into the periphery of the 
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Figure 6.6 Generalized Model of Aβ1-40 micelle (red indicates polar N-terminus) interacting 
with an Aβ aggregation mediator (blue indicates oligolysine unit). (A) Mediator intercalates 
the core of the Aβ micelle. (B) Insertion of mediator into Aβ micelle. (C) Capping of micelle 
with mediator.  
 
 The differences in the SFM and TEM data suggest the sample preparation of the two 
techniques provide detail about structures in different locations of solution. SFM sample 
preparation involves placing an aliquot after mixing of the sample onto mica, whereas in TEM, 
sample preparation requires the placement of a grid on top of a droplet of an aliquot of agitated 
Aβ1-40 solution.  The placement of this drop may determine what types of aggregates were seen 
as any surface-active complexes may have been seen more easily by TEM than SFM.  However, 
both SFM and TEM, found that AMY-1, AMY-2, and Murphy inhibitor formed aggregates with 
Aβ1-40 which differed to normally seen aggregate stages of Aβ fibril formation in the absence of 
such mediators. 
6.4 Conclusion 
 Aggregation mediation and fibril inhibition can be directly observed by SFM and TEM 
analysis.  The very large aggregate formed by the 1:1 interaction of AMY-2 and Aβ1-40 is thought 
to be caused by the position of the lysines on the N-terminus of the peptide.  The observation of 
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large aggregate complexes between Aβ1-40 and an aggregation mediator with an oligolysine unit 
on its N-terminus of KLVFF has been previously reported by Dr. Regina Murphy.3,4 
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Fibril-Forming Cyclic Peptides: A Possible Model for Describing 




 Many pathological diseases are associated with the presence of bundles and plaques 
containing fibril formations.  A majority of these fibril forming peptides contain a β-sheet motif.  
The cyclic peptides presented here form β-sheet conformations in both solution and while 
adsorbed on HOPG.  The ability to form assemblies and fibrils were observed on HOPG, but not 
on C18-terminated Au.  The adsorption and propagation of these cyclic peptides on thermally 
provided pits on HOPG provide evidence that the edge of graphite is important in anchoring 
these cyclic peptides.  The seeding of β-amyloid 1-40 was evident on previously exposed cyclic 
peptide HOPG surfaces by the observation of layers and nucleations ontop of these β-amyloid 
layers.  
  A model for describing fibril formation in general remains elusive as each fibril-forming 
peptide contains different attributes.  We describe in this work, two cyclic peptides which 
contain both a hydrophobic segment similar to that of β-amyloid protein and a synthetic β-turn 
which model the β-amyloid protein.  In doing so, we have found these cyclic peptides to be 
potent fibril formers in solution, and they nucleate and form fibrillar structures at select locations 
on highly-oriented pyrolytic graphite (HOPG). 
7.2 Fibril-Forming Cyclic Peptides 
 The versatility of peptide tubule or fibril construction and their capabilities are evidenced 
by the different designs from which they are built.1  The fabrication of tubules of cyclo-[(L-Phe-
D-N-MeAla-)4] has been proposed for size-selective transportation through membranes.2,3  The 
transportation of charge in microelectronics may be accomplished with junctions across biotin-
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coated Au substrates made from avidin-coated peptide tubules.4  The presence of a hydrophobic 
cavity and specific internal diameter enables the cysteine-based cyclo-bisamide tubule to aid in 
intercalation and delivery of target drugs.5  
7.3 An Interest in Fibril Formation 
 Our interest in fibril formation is the result of their role in neurodegenerative diseases, 
such as Alzheimer’s disease.  The fibril formation associated with these proteins originate from a 
misfold in the protein under favorable conditions. Protein misfolding has been identified as the 
major player in a host of diseases in which the native conformation of the protein is converted 
into a more β–sheet conformer which also is resistant to proteolysis and treatment.5  Proteins 
which are rich in this ability to adopt β–sheet conformations have been noted in several proteins 
with dissimilar sequences.6  The aggregation of these proteins further stabilize such β 
conformations by screening hydrophobic sections from the bulk solution.5 β-sheet rich proteins, 
such as β–amyloid, transthyretin, huntington, prion, and amylin proteins, are known to aggregate 
into fibril structures.5,7  However, even α–helical proteins, under certain conditions can be made 
to convert into fibrils.6   
The β–sheet forming peptide, β–amyloid (1-40), a main cleavage fragment of the neuron 
trans-membrane, amyloid-precursor protein, has been noted to cause amyloid fibrils in the brains 
of individuals stricken with Alzheimer’s disease.  The ability of this peptide to convert to fibrils 
is due in part to two essential components, a very hydrophobic amino acid sequence component 
adjacent to an amino acid sequence region which adopts a β-turn.  This hydrophobic amino acid 
sequence, KLVFF, is being used by researchers as a part of a recognition element within 
designed constructs which would antagonize the toxic conformational pathway of β–amyloid.8-12  
However, KLVFF itself does not form fibrils.13 The models developed herein contain the 
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KLVFF sequence known to promote aggregation, and a synthetic β-turn to resemble the VGSN 
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7.4 Materials and Methods 
7.4.1 Peptide Synthesis and Purification  
            The cyclic peptides were synthesized in the Louisiana State University Protein Facility.  
A solid-phase, continuous-flow chemistry on an Applied Biosystems PIONEER instrument was 
used in the synthesis of these cyclic peptides. An initial linear peptide was constructed on a PAL-
PEG-PS resin using F-moc protected amino acids and TBTU and HOBT activation. Use of allyl-
protected glutamic acid allowed deprotection with tetrakistriphenylphosphine palladium, 
followed by cyclization with PyAOP activation, as the final step of a fully automated synthesis.  
Cleavage of the peptide from the resin was accomplished using a trifluoroacetic acid-based 
reagent (88% TFA, 5% water, 5% phenol, 2% triisopropylsilane) for 2 hours, followed by a 
precipitation in cold diethyl ether.  The crude peptide was purified by reverse-phase HPLC on a 
Waters Delta Prep system, incorporating a Waters 486 detector operating at 220 nm wavelength 
and a Waters C4 Delta-Pak column (10 nm pore size, 15 µm particle size), 200 x 25 mm.  The 
gradient was composed of water and acetonitrile, each containing 0.1% TFA.  Initial conditions 
were 90% water/10% acetonitrile.  Final conditions were 60 % water and 40 % acetonitrile, run 
over 60 minutes. The molecules of interest eluted at 22% acetonitrile. Fractions were freeze-
dried prior to checking the purity of each on a Vydac 218TP54 column, using a Waters 600S 
pump and a Waters 996 photodiode array detector.  Fractions with purities >95% determined by 
HPLC were pooled and dried again.  The net peptide content of the finished product was 
determined by quantitative amino acid analysis on a Dionex AAA-Direct system.  Molecular 
weights of these pure peptides were verified by MALDI mass spectrometry.  The peptide was 





7.4.2    Preparation of Samples for Scanning Force Microscopy 
 Sample preparation was accomplished by placing an aliquot of 5 µL of 50 µM MCP-1 or 
MCP-2 in 18 MΩ deionized water (final pH 2.9) on various surfaces.  Such surfaces used for 
SFM were hydrophilic mica (ASTM V–2 Grade 3 ruby muscovite, Lawrence & Co.) and 
hydrophobic highly-oriented pyrolytic graphite obtained from Dr. Arthur Moore at Advanced 
Ceramic Corporation. HOPG surfaces possessing mono-atomic deep pit domains were achieved 
by heating the HOPG at 650 ºC for 30 minutes in a furnace in air.  Another hydrophobic surface, 
C18-terminated Au, was prepared in our laboratory by adsorbing octadecane-1-thiol terminated 
thiol on Au-coated mica [(Au 111)].  
Silicon (111) wafers of n-type (Ar-doped) Si (111) were also employed in our studies and 
were obtained from Virginia Semiconductor.  The silicon was prepared by removing organic 
materials from the surface with RCA-1 cleaning (1:1:6) NH4OH: H2O2: H2O and removing the 
SiO2  layer with etching techniques NH4F: HF.14-17  This left a hydride-terminated Si surface, 
which has been shown to be hydrophobic and ordered. 
  Cleavage of mica was done by separating two thin sheets of (1 cm x 1 cm) mica using a 
razor blade and then pulling them apart using tweezers.  The cleavage of graphite was done by 
removing a thin veneer of graphite from a bulk sample with the aid of one-sided Scotch tape.  
The freshly exposed surfaces were then placed face up on a flat surface, and an aliquot of 5 µL 
sample was placed ontop this surface for 5 minutes.  The surface was then gently dried with a 
stream of nitrogen. After drying, the substrates were glued to a magnetic puck with the aid of a 
Gluespot disk from Digital Instruments (vendor catalog reference code STKYDOT).  The 
samples were either imaged immediately by scanning force microscopy immediately or after 
storage  inside an Entegris polypropylene wafer (vendor number H22-101-0615 and H22-10-
06115 for the tray and lid) for later analysis. 
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7.4.3 Preparation of Samples for Circular Dichroism 
 An Aviv circular dichroism spectrometer model 62 DS with Igor Pro version 4.0 software 
was used to plot the secondary structure of these cyclic peptides.  Both cyclic peptides were 
dissolved in an aqueous solution at pH 3.  
7.4.4 Preparation of Samples for Dynamic Light Scattering 
 
 Solutions were analyzed by a blue line 488 nm laser at 100 mW output. Samples were 
placed in screw capped Pyrex 9826 tubes (vendor number 60827-453) from VWR Scientific. 
Measurements could be obtained with volumes as low as 250 µL in these tubes.  The samples 
were kept at room temperature between DLS measurements except for incubations at 50 ºC.  
Multi–run measurements were performed every 60 seconds at a scattering angle of 90º. A third 
cumulant fit algorithm on the ALV software was used to determine the diffusion coefficient and 
size of the particle of interest. 
7.4.5 Preparation of Samples for Tensiometry 
 Surface pressure measurements were conducted on solutions using the du Nuoy ring 
method on a Sigma 703 tensiometer.  A platinum ring from (CSC Scientific Company) was able 
to detect 500 µL of starting volume of each cyclic peptide.  The peptide solution was placed on 
an ethanol-cleaned watch glass and the ring was submerged and then removed for a 5 recordings 
of the surface pressure.  The addition of 18 MΩ water and agitation of the solution on the 
watchglass by pipettor action allowed a range of concentrations to be studied. 
7.5     Discovery of the Fibril-Forming Nature of These Cyclic Peptides 
Assays used for determining the efficacy of peptide constructs to inhibit fibril formation 
revealed fibril morphology previously unknown to β–Amyloid.  This unknown, long (sometimes 
greater than 20 microns), and very linear fibril morphology was found to coexist along with the 
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smaller β–amyloid fibrils.  Therefore, these cyclic peptides did not prevent the fibril formation of 
β–amyloid, but thrived as potent fibril formers of their own.  
Even though these cyclic peptides (MCP-1 and MCP-2) formed fibrils, their apparent 
affinity for template formation and aggregation on hydrophobic surfaces provides an analogy of 
the possible conformational changes of proteins which occur at the membrane surface in vivo.18  
Also, such surface induced aggregation may enable the building of constructs for nanostructure 

























Figure 7.2 SFM image of MCP-2 and Aβ1-40 fibrils adsorbed on HOPG obtained by 
incubating 50 mM phosphate and 150 mM NaCl at pH 7.2 for 14 hrs. at 37 ºC. Image 
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7.6 Microscopic Evidence of Fibril Formation 
Evidence of the fibril forming nature of these cyclic peptides was obtained from scanning 
force microscopy (SFM).  Images obtained with this method exhibited adsorbed layers of MCP-1 
and MCP-2 with fibril formation only on the hydrophobic surface (HOPG).  The HOPG step 
edges evidently act as nucleation sites for formation of MCP-1 and MCP-2 layers.  Sub-
monolayers seem to run nearly orthogonal to the step edge on graphite surfaces but tend to veer 
away from an adjoining upper atomic plane (step edge) as the peptide structures approach the 
adjoining step edge. as seen in Figure 7.3.  The deposits on mica of MCP-1 aggregates (Figure 
7.3 A) measured 5.9 ± 1.0 nm in height whereas MCP-2 deposition (Figure 7.3 C) were 1.7 ± 0.6 
nm high aggregates.  These MCP-1 and MCP-2 aggregates on mica do not seem to possess any 
order.  However, very different morphologies of the cyclic peptides were observed when HOPG 
was used as the substrate.  HOPG surfaces exposed to MCP-1 and MCP-2 for 5 min. all 
exhibited fractal-like deposits which appear to have been initiated at the step edges of the HOPG 
atomic planes (step height is 3.4 Å  for HOPG).  In addition, the surfaces for both MCP-1 and 
MCP-2 possess > 10 µm-long fibrillar structures.  These fibrillar structures grow from the 
presence of the existing monolayers.  This observation of fibril formation initiated by an ordered 
monolayer on HOPG has also been noted with elastin-like peptides.1  
  Control experiments with pH 3 solutions not containing MCP-1or MCP-2 do not lead to 
the observation of any adsorbed fractal species nor any fibrillar material, indicating the cyclic 
peptides were responsible for the fractal and fibrillar deposits. MCP-1 has a monolayer much 
smaller in height than MCP-2.  MCP-1 monolayer height is 0.47 ± 0.1 nm (Figure 7.3 B) 
whereas MCP-2 monolayer height is 1.7 ± 0.2 nm as seen in Figure 7.3 D.  The fibrils formed 
from MCP-1 were 2.3, 3.4 and 4.1 nm in height (Figure 7.3 B), whereas the large fibril seen in 
MCP-2 was 8.1 nm in height.   Possible lateral associations of fibrils formed by MCP-1 and the 
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large fibril formations of MCP-2 are displayed in Figure 7.5.  Cross-sectional analyses of MCP-1 
fibrils yielded values of 7.4 ± 0.4 nm for the height of the fibrils, whereas the MCP-2 fibrils were 
~9 nm in height with assemblies 1.4 to 1.6 nm in height (Figure 7.4).  
 Time dependent studies of each cyclic peptide are represented in Figure 7.5.  At an 
adsorption time of 5 seconds, MCP-1 displayed a monolayer of material, after 5 minutes, fractal 
crystallization took place, and after 30 minutes of exposure to HOPG, fibrils were seen on the 
surface.  MCP-2 displayed different attributes at the same adsorption times.  MCP-2 displayed 
small spherical agglomerations with small propagating structures at a 5 second adsorption and 
further propagation of these structures at 5 minutes.  After a 30 minute adsorption, fibrils were 
observed. 
7.7 Dependence of Fibril Formation on Hydrophobicity or Surface Orientation of 
 Substrate [(C18H37S-Au(111)] 
 
 Hydrophobic C18-terminated Au surfaces were employed so as to allow the 
determination of whether fibril formation was influenced by surface hydrophobicity.  The 
hydrophobic C18-thiol monolayer on Au(111) did not display any apparent assembly or fibril 
formation for either cyclic peptide (Figure 7.6).  However, the exposure of HOPG to an aliquot 
from the same solution of these cyclic peptides led to observations of large fibrils (upwards of 20 
microns in length) on (0001) HOPG. 
To further probe the role of surface orientation with fibril formation, a surface with a 
different orientation, Si(111), was employed.  No fibril formation from either cyclic peptide was 
observed on Si(111) before cleaning.  Si(111) without cleaning has a very hydrophobic surface 
due to a layer of SiO2 and carbonaceous deposits.19 However, cleaned Si(111) displays a surface 












   
 




























Figure 7.3 5 µm x 5 µm SFM image of fibril formation on highly-oriented pyrolytic 
graphite of peptides dissolved in 18 MΩ deionized water (pH 2.9) at 5 min. adsorption. (A) 
50 µM MCP-1 on mica, (B) 50 µM MCP-1 on HOPG, (C) 50 µM MCP-2 on mica, (D) 50 





































Figure 7.4 Cross-sectional analyses of both fibrils and fractal assemblies on HOPG. (A) 
MCP-1 fibrils of 7.1, 7.9, and 7.4 nm in height. (B) MCP-2 fibril is 9.1 nm in height and 
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Figure 7.5 Time dependent evidence provided by SFM images of MCP-1 and MCP-2.   
Images are of MCP-1 (A) and MCP-2 (B) after a 5 second adsorption, MCP-1 (C) and 
MCP 2 (D) after a 5 minute adsorption, and  MCP-1 (E) and MCP-2 (F) after 30 minutes of 






Both MCP-1 and MCP-2 were found not to form fractal crystallizations on cleaned Si(111).  
However, the cleaned Si(111) displayed a roughness that may not be suitable for cyclic peptide 
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Figure 7.6 5 µm x 5 µm SFM images of C18-thiol terminated Au. (A) C18-terminated thiol 




7.8 Cyclic Peptide Character Defines Fibril Formation 
 These cyclic peptides adopt a β-sheet conformation in both solution and while adsorbed 
on HOPG evidenced by circular dichroism (CD) and reflection absorption infrared spectroscopy 
(RAIRS).  The formation of both cyclic peptide fibrils on HOPG surfaces have been noted at 
both acidic (pH = 2.9) and neutral (pH = 7.4) conditions (Figure 7.7).  The formation of these 
fibrils is thought to depend on the overall charge on the cyclic peptide. 
HOPG is comprised of carbon atoms covalently bonded  through sp2 bonding within each 
layer.20  Although HOPG is inert along its basal plane, the step edges have faster electron 
kinetics and may undergo surface oxidation leading to a creation of oxidized carbon species on 
the edge plane.21-23  Thus, the edge plane of HOPG has been found to be more reactive and prone 
to adsorption than at the basal plane.22  Each cyclic peptide contains lysines which have a 
terminal pKa of (10.8).24  At both acidic and neutral pH, the surface carboxyl group is partially 
ionized leaving a negatively charged surface domain with which a positive NH3+ from lysine can 
interact. 
 In a high pH environment (pH of 12), the cyclic peptides do not have a positive charge 
and the adsorbed layers do not display the fractal crystallization or large fibril formations 
identified at a pH below the terminal lysine pKa.  The lack of aggregate order may be attributed 
to the lack of positive terminal amine groups available to interact with the still negatively 
charged carboxyl group found on the HOPG.24   
7.9 Microscopic Evidence of Cyclic Peptide Nucleation at Exposed HOPG Domains 
 
 Heated HOPG surfaces containing monoatomic-deep pits were observed to cause 
nucleation and radial growth of cyclic peptide away from the periphery of the HOPG pits as seen 
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Figure 7.7 10 µm x 10 µm SFM images of cyclic peptide solutions adsorbed on HOPG. (A) 
MCP-1 at pH 7.4; (B) MCP-2 at pH 7.4; (C) MCP-1 at pH 12; (D) MCP-2 at pH 12. White 
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Figure 7.8 5 µm x 5 µm SFM images of (A) 50 µM MCP-1 and (B) 50 µM  MCP-2 adsorbed 
on HOPG preheated at 650 ºC for 30 minutes. The pH of each cyclic peptide’s aqueous 
solution was 3. White bar is 1 µm in length. 
 
MCP-1 displayed a monolayer of 1.6 ± 0.4 nm in height around the outside of the pit of HOPG.  
MCP-2 displayed a monolayer of 1.8 ± 0.2 nm in height around the outside of a 0.83 nm deep 
HOPG pit. 
7.10 Behavior of Cyclic Peptide Solutions 
 The appearance of the cyclic peptide containing solutions when placed onto substrates 
used for scanning probe microscopy (graphite, mica, gold, and silicon) was very hydrophobic. 
The removal of aliquots from these solutions displayed little surface activity as the solutions did 
not foam when agitated. Negligible surface activity of both cyclic peptides was observed by 
tensiometry as detailed in Figure 7.6.  These solutions tended to bead well on various surfaces 
and displayed this attribute on the inner walls of polypropylene microcentrifuge tubes and the 
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inner walls of pipet tips.  Both MCP-1 and MCP-2 did not display any significant surface activity 
















Figure 7.9 Surface pressure measurements of MCP-1, represented as triangles, and MCP-
2, represented as squares. Aqueous cyclic peptide solutions were at a pH of 3. 
Concentrations were 50 µM, 500 µM, 1 mM, and 2 mM in deionized water. 
 
7.11 Solution Studies of Possible Cyclic Peptide Growth in the Absence of HOPG 
 Dynamic light scattering was used to determine whether these fibrils evolve in solution or 
evolve only when the peptide is near a nucleating and hydrophobic surface.  In solution, it was 
found that the MCP-1 cyclic peptide grew at a faster rate than did MCP-2 (Figure 7.7).  MCP-1 
grew large structures after 3 days whereas MCP-2 had a small amount of growth over 6 days. At 
3 mM MCP-2, the particle size was 75 ± 0.8 nm on the first day and increased to 89 ± 2 nm at 3 
days incubated at room temperature and at a pH of 3.  
 For MCP-1 under similar conditions, initial particle size was 82 ± 2 nm on the first day 
and 142 ±18 nm on the third day of incubation.  However, no correlation in size between light 
scattering and microscopy could be made on either HOPG or mica.  Once the solution was 
placed upon graphite, the cyclic peptides grew into assemblies and fibrils longer than the sizes 




















recorded in solution by light scattering and furthermore aliquots of these solutions spotted on 














Figure 7.10 DLS Detection of the Growth of Each Cyclic Peptide in Solution at a pH of 3. 
 
7.12 Circular Dichroism Studies of Cyclic Peptides 
 The secondary structure of each cyclic peptide was assessed in its dissolved state 
(aqueous solution) at pH 3.  Figure 7.11 provides evidence which shows that both cyclic peptides 
































Figure 7.11 Circular Dichroism Spectrum of MCP-1 and MCP-2 in an aqueous pH 3 
solution. 
 
7.13 Infrared Studies of Cyclic Peptide Adsorption on HOPG 
 A shift in the amide I and II bands was observed for each cyclic peptide when adsorbed 
on HOPG.  Within an isotropic medium such as KBr, MCP-1 had an amide I band position of 
1671 cm -1, indicative of a β-sheet, and an amide band II of 1531 cm-1. Also, MCP-2 had an 
amide I band of 1676 cm-1, indicative of β-sheet, and an amide II band of  
1537 cm -1.   
 When adsorbed to HOPG, MCP-1 displayed an amide I band at 1691 cm-1, also indicative 
of β-sheet, and an amide II band at 1556 cm-1.  MCP-2 displayed an amide I band at 1691 cm-1 
and an amide II band at 1559 cm-1. 
7.14 Adsorbed Cyclic Peptides Enable Aggregation of β-Amyloid (1-40) 
 
 Monolayers of Aβ1-40 were found to be produced when adsorbed to an existing MCP 
covered surface.  Surfaces chosen for depositing β-amyloid were from the 5 minute adsorptions 
of either MCP-1 or 2 (Figure 7.6 C, D).  Aβ1-40 adsorbed on pristine HOPG displayed only small 
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aggregates of 1-11 nm in height (Figure 7.13A).  Figure 7.13B demonstrates Aβ1-40 deposition on 
a previously deposited MCP-2 surface shown before (Figure 7.6D).   
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Figure 7.12 RAIRS spectra of Amide I and II bands occur when cyclic peptides are 
adsorbed on HOPG. (A)  0.5 mg of MCP-1 and MCP-2 in an isotropic medium such as 
KBr. (B) 500 µM MCP-1 and MCP-2 at pH 3 adsorbed on HOPG. 
 
 
Here, Aβ1-40 covered the pre-existing layer of MCP-2 and had nucleations of 10-16 nm on top of 
the layer. Aβ1-40 deposition on pre-existing MCP-1 monolayer (Figure 7.6 C) displayed an 
adsorbed layer of β-amyloid and nucleations of 6-13 nm in height (Figure 7.13 C).  The pre-
existing monolayer of either cyclic peptide is thought to induce a disorder to order transition 
which would allow fibril formation of β-amyloid to take place.  Such substrate-derived formation 
of fibrils has been reported with elastin-like peptides.1    
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Figure 7.13  5 µm x 5 µm SFM images of Aβ1-40 adsorption on (A) HOPG; (B) HOPG with 
pre-existing MCP-2 layer; (C) HOPG with pre-existing MCP-1 layer. White bar is  
1 µm.  Z-range is 10 nm. 
 
 
7.15 Model of Peptide Nucleation and Growth on HOPG 
  
 Models for the orientation and growth of each cyclic peptide have been proposed in 
Figure 7.14.  In Figure 7.14 A, MCP-1 is proposed to lay parallel and propagate across the basal 
plane of HOPG after an initial adsorption to the step edge of HOPG. SFM software cross-
sectional analysis of the MCP-1 monolayer demonstrated a monolayer height of 4 Å.  MCP-2, in 
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Figure 7.14 B displayed a monolayer height by cross-sectional analysis of 17 Å due to the 

























Figure 7.14 Models of Cyclic Peptide Adsorption on HOPG. (A) MCP-1 laying parallel to 
the surface and (B) MCP-2 facing perpendicular to the surface.  Each blue ring represents 




 Scanning force microscopy images of cyclic peptides adsorbed to hydrophobic graphite 
provided evidence of surface-induced self-assembly.  The hydrophobic surface has been 
identified as a promoter of protein conformation.18,25,26  Observations that amyloid deposition 
orientates according to the symmetry of the graphite surface also was believed to play a factor 
here in cyclic peptide fibril formation.18,26   Cyclic peptide organization on the surface began 
with the adsorption of cyclic peptide aggregates followed by propagation of such aggregates in 
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orientated directions.  These orientations allow the nucleation and growth of fibrils.  Evidence of 
this phenomenon was identified with heated HOPG.  The production of pits in the HOPG created 
sites where both cyclic peptides could nucleate and grow radialy around the periphery of the pit.  
The presence of either carboxyl or phenolic groups on these exposed sites is thought to induce 
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Summary of Conclusions and Future Directions 
8.1 Summary of Conclusions 
 
8.1.1 β-Amyloid Aggregation Can Be Controlled 
 
A stable initial stock solution environment is critical for eliminating non β-amyloid 
nucleation and aggregate formation. It is highly suggested that removal of non–amyloid 
nucleating sites such as dust, metal impurities, and rough inner walled vials should be performed. 
These potential nucleation facilitators can speed an otherwise slow–nucleation and growth 
process. The rapid presence of turbid stock solutions after dissolving the peptide in rough inner 
walled vials has led to the belief that inner wall roughness can play a major role in the amount of 
aggregate formation.  Elimination of dust and pre-formed β-amyloid aggregates can be removed 
by filtering. While removing uncontrollable aggregation, inducing and controlling β-amyloid 
aggregate formation can be done with the aid of increasing the ionic strength of the buffer system 
used. 
8.1.2   Characterization of Peptide Aggregation Mediators 
 The surface activity of each peptide-based aggregation mediator at various concentrations 
enabled a determination of the extent of each mediator’s surfactant-like properties.  It was found 
that both AMY-1 and AMY-2 display surface activity around 1 mM, whereas, the mediator 
developed by Dr. Regina Murphy did not.  Even though surface activity was found for AMY-1 
and AMY-2, the concentrations at which they would form micelles are 20 fold larger than the 
concentrations found to disrupt Aβ1-40 fibril formation.  Thus, the interactions between each 
mediator and Aβ1-40 are not one involving micellar interactions.  It was also important to ensure 
that each mediator did not aggregate substantially with itself.  SFM studies confirmed that AMY-
1 and Murphy sparsely self-aggregated whereas AMY-2 tended to form monolayers on mica. 
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8.1.3 Surface Activity Aids in Determining Selectivity 
The surface-active properties of the peptide-aggregation mediator and fibril forming 
peptides were also assessed by tensiometry to understand the interactions made between them 
before any aggregation occurred. It was found that the complex formed between AMY-1 and 
Aβ1-40 was more surface-active than AMY-1 or Aβ1-40 alone.  AMY-2 was found to form a more 
surface-active complex with Aβ1-40, Aβ25-35, and Amylin20-29.  The mediator developed by Dr. 
Regina Murphy did not form a complex which had a higher surface active property than the 
mediator or fibril forming peptide alone.  Therefore, AMY-1 formed a complex with only Aβ1-40 
which was more surface-active than the mediator or Aβ1-40 alone. 
8.1.4 Efficacy of Aggregation Mediators 
 AMY-1, AMY-2, and Dr. Regina Murphy’s mediator all displayed an ability to disrupt 
fibril formation.  AMY-1 was able to mediate Aβ1-40 amyloid aggregation and produced spherical 
agglomerations.  The mediator developed by Dr. Regina Murphy mediated the aggregation of 
Aβ1-40 in the form of amorphous aggregates and branched linear aggregates, but no fibril 
morphologies similar to Aβ1-40 fibrils were present.  AMY-2 displayed rapid interaction and 
aggregation with Aβ1-40 in the form of a colloidal precipitate.  It was found that AMY-2 was able 
to form large amorphous aggregates and inhibited fibril formation.    
8.1.5 Cyclic Peptides Generate a Model for Protein Aggregation and Fibril Formation 
 
Although initially proposed as inhibitors of fibril formation, both MCP-1 and MCP-2 
displayed significant fibril formation of their own.  Their β-sheet properties found by CD and 
RAIRS are properties associated with many fibril forming peptides.1  Their ability to template 
only on edge planes of HOPG is thought to be driven by electrostatic interactions between the 
lysines located on the cyclic peptides and the oxidized carbon species located on the edge of the 
HOPG.2-4  Evidence of electrostatic interactions was supported by the observation of cyclic 
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peptide adsorption and radial propagation from thermally induced holes in HOPG and also the 
inability of cyclic peptide fractal crystallization or large fibril formation at pH 11 (terminal 
Lysine pka is 10.8).  The monolayers of each cyclic peptide on HOPG have been shown to 
promote Aβ1-40 monolayer formation and nucleation demonstrating the disorder to order 
transition needed for aggregation and eventual fibril formation.5 
8.2 Future Directions 
The work presented here mainly dealt with the end point of the interactions between Aβ1-
40 and peptide-based aggregation mediators. A more comprehensive study is needed to determine 
exactly the modes of interaction between Aβ1-40 and a mediator.  Understanding the affinity for 
each mediator to bind to Aβ1-40 could be accomplished using surface plasmon resonance (SPR) to 
determine the binding constants of each mediator (AMY-1, AMY-2, and others) to an 
immobilized array of Aβ1-40.6  Binding isotherms can be used to describe these mediator/Aβ1-40 
complex formations at the air-water interface.7   
Another tool for determining modes of interaction would be to detect the interactions 
made between mediators and Aβ1-40 tethered to Au nano particles by in situ RAIRS.  This would 
give insight into whether the interaction with each mediator creates an α-helix, parallel or 
antiparallel β-sheet conformation of Aβ1-40. β-Sheet conformations on surfaces, such as found 
with MCP-1 and 2 on HOPG, may induce Aβ1-40 fibril formation.  Cyclic peptide monolayers on 
HOPG have been observed to induce Aβ1-40 layer formation.  In situ Tapping Mode SFM could 
be used to watch the growth of these fibrils with time.   
Understanding the role of these cyclic peptides on adsorbing onto HOPG is also needed.  
The capping of exposed sites of HOPG with tertiary butyl groups would aid in determining 
whether the oxidized carbon species located on these sites are the main factor in templating the 
cyclic peptides described here.4  In doing so, it is hoped that the elimination of negative charge 
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on these sites will allow for investigation of whether any electrostatic interactions occur between 
HOPG and the lysine groups on each cyclic peptide. Additionally, the question of the 
reversibility of the cyclic peptide assembly process could be probed by making the fibrillar 
species on HOPG followed by changing the pH or ionic strength (or maybe addition of 
surfactants). If the fibrils de-assemble, then such assemblies might be useful in molecule delivery 
applications. 
From a materials science point of view, one could think of using the HOPG surfaces to 
make fibrils and subsequently isolate them to see if they possess any void space (are they tubes 
or true fibrils?). One could use scanning electron microscopy to change the orientation of these 
tubules or fibrils to see if they are indeed hollow. The outcomes from such endeavors might lead 
to the possibility of using the cyclic peptide assemblies as templates for making metallic, 
inorganic semi-conductor or polymeric nanostructures. For example, certain metal ions/metal ion 
complexes might coordinate to the amino acid residues of the assemblies and then their 
subsequent reduction would lead to production of metallic nanometer-diameter wires with 
lengths on the micron scale. Furthermore, Fullerene nanotubes, such as single-walled carbon 
nanotubes or multi-walled carbon nanotubes, terminated with carboxylic acids8, could be used to 
make protein-coated nanotubes, which might make the Fullerene tubes amenable to use in a 
variety of media or allow for fabrication of complex protein-carbon nanotube structures.    
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